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Abstract

Background: Pulmonary arterial hypertension (PAH) is a rapidly progressive disease.
There is currently no cure; thus treatment is aimed at prolonging survival, improving
functional status (FS), and symptom mitigation. Symptom burden (SB) can impact quality
of life (QOL), and lead to increased healthcare utilization. Palliative care (PC) has been
associated with higher QOL, decreased depression, aggressive care, and mortality. The
Institute of Medicine’s (IOM) recent report supports earlier integration of PC for people
living with serious illness. Detection of patients at high risk for heavy SB may help to
identify patients who could benefit from earlier integration of PC into standard care.
Objectives: Describe symptom occurrence and characteristics, and examine relationships
between selected demographics, clinical characteristics, healthcare utilization patterns, and
SB in patients with PAH.
Methods: A descriptive correlational study was conducted with a consecutive sample of
PAH patients recruited at an academic medical center. Participants completed questionnaires
at the time of their usual clinic visit. Demographics and perceived SB using the Memorial
Symptom Assessment Scale (MSAS) were collected. A chart audit to collect clinical
characteristics, and healthcare utilization patterns was completed. Data were analyzed with
descriptive and correlational statistics.
Results: One hundred percent reported some symptomology. The mean number of
symptoms reported was 16.0 (SD +/- 6.8), range of 1 to 29; three most common were, lack
of energy (92%), shortness of breath (80%), and feeling drowsy (78%). Working patients,
reported significantly lower Global Distress Index scores (GDI) (p = .006), physical

subscale scores (PHYS) ip = .003), and psychological subscale scores (PSYCH) (p = .035)
compared to those not working. Patients who made more than 2 clinic visits within the
previous six months had significantly higher GDI scores (p = .001), PHYS subscale scores
(p < .001), and PSYCH subscale scores (p = .035). Patients receiving endothelin
antagonists reported a statistically lower number of symptoms experienced (p = .012)
compared to patient not receiving these medications. Patients on intravenous prostanoid
therapy had more emergency department visits (p < .001) and hospitalizations ip = .049)
compared to patients not on intravenous prostanoid medications.
Implications: Patients with PAH experience heavy SB. Patients with heavier reported SB
include: those not working, not receiving endothelin antagonist medications, in FC III or IV,
and those with more than 2 clinic visits in a 6-month period.
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Chapter I
Introduction
Statement of the Problem
Symptom burden (SB) is the global appraisal of the symptom experience, which
can result from both the disease process and its treatment. It is a healthcare priority due to
its impact on the individual, the family unit, and society as a whole. The National
Institute of Nursing Research (NINR, 2011) put forth their research priorities in 2011,
which included symptom management and palliative care with goals of improving life
quality in chronic and life threatening illness. “Specific research topics and activities
include: relief of pain, suffering, and distressing symptoms through effective palliative
care: understanding and facilitating decision making by patients, caregivers, and
providers” (p. 19).
SB is a phenomena often associated with chronic and terminal disease,
particularly cancer. In developing the measure, Symptom Experience Index (SEI), Fu,
McDaniel, and Rhodes (2007) defined SB as the extent of physiological and
psychological suffering resulting from a person’s response to symptom manifestation.
Cleeland (2007) spoke to the implicit negative connotations of symptoms in general,
terming SB as a collective imposition of distress on a person. The self-regulation theory
(Leventhal & Johnson, 1983) differentiates the experience of symptoms into the
incidence of a symptom and the emotional distress associated with it. The latter aspect

could be considered SB. Suffering arising from symptom experience is influenced by the
degree of perceived departure from one’s baseline function, sensation, appearance, and
the individual analysis of the value of these events (Rhodes et al., 2000). Thus symptom
distress is the appraisal of the suffering and degree of burden.

Pulmonary arterial hypertension (PAH) patients are a unique population who face
a heavy symptom burden associated with a myriad of factors related to the disease and its
treatment (Ferrari et al., 2013; Khan 2011; Matura et al., 2012; Matura et al., 2014; Oudiz,
2012). Distinguishing aspects particular to PAH patients are the significant onus imposed
by the inconvenience and side effects of the medication regimen, the lack of wider
understanding regarding the disease which often heightens social isolation, and financial
concerns of medications (Ferrari et al., 2013; Galie et al., 2009; Khan, 2011; Matura et
al., 2010; Matura et al., 2014a; Matura et al., 2014b; McDonough et al., 2011; Oudiz,
2012). An adequate measure of SB is important in order to optimally measure
improvements from medication adjustments or other interventions aimed at symptom
mitigation such as palliative care integration. To date, there have been limited studies
measuring SB in advanced PAH or patients in NYHA functional class III or IV. This
proposed study’s aims are to describe: demographics, clinical characteristics, and
healthcare utilization patterns related to the SB experience of patients with advanced
PAH.

Background and Significance
PAH is a rapidly progressive and chronic disease in which excessive proliferation
of the smooth muscle and vasculopathy lead to constrictive remodeling of the pulmonary

vasculature (Galie, 2009; Task Force for Diagnosis and Treatment of Pulmonary
Hypertension of European Society of Cardiology ESC, 2009; Traiger, 2007). PAH has a
myriad of etiologies with the majority arising from familial disease, idiopathic, or
associated with other diseases. These conditions, in order of prevalence, include: collagen
vascular disease, connective tissue disease which constitutes almost 50% of this subset,
congenital heart disease (20%), portal hypertension (10%), drugs or toxins, (10%), HIV
(4%), and other disease states (6%) (Badesch et al., 2010).
Pulmonary hypertension (PH) classification underwent revision at the 5th World
Symposium on PH in 2013. The disease was broken down into two broad categories:
PAH and non-PAH PH. Pulmonary arterial hypertension classification includes
idiopathic: hereditary, drug or toxin induced, associated with, and a subclass of PAH. The
“associated with” group has subgroups of connective tissue disease, HIV, portal
hypertension, systemic-pulmonaiy shunts, schistosomiasis, and chronic hemolytic
anemia (Table 1).
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Table 1
Clinical Classification o f Pulmonary Hypertension (PH)

1. Pulmonary Arterial Hypertension
o Idiopathic
o Hereditary
o Drug/toxin induced
o Associated with:
• Connective tissue disease
• HIV infection
• Portal hypertension
• Congenital heart disease
• Systemic-pulmonary shunts
• Schistosomiasis
• Chronic hemolytic anemia
lb. Subclass of PAH
■ Pulmonary veno-occlusive disease and/or pulmonary capillary
hemangiomatosis
■ Persistent PH of the newborn
2. PH due to left heart disease
3. PH due to lung diseases and/or hypoxia
4. PH due to chronic thromboembolic pulmonary hypertension
5. PH due to unclear or multifactorial etiologies

Note. Adapted from Ferrari, P., Armstrong, I., Aldrighetti, R., Howard, L.,
Ryftenius, H., Fisher, A .,... Guillevan, L. (2013). Impact o f pulmonary arterial
hypertension on the lives o f patients and carers. Presented at the 5th World Symposium
on Pulmonary Hypertension, Nice, France.
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The most definite diagnosis of PAH is achieved with a right heart catheterization
to assess pulmonary artery pressures (PAP) (Lourenco et al., 2012). An elevated mean
PAP of 25 mmHg or greater at rest or 30 mmHg or greater with exercise, a pulmonary
capillary wedge pressure </=15, and a pulmonary vascular resistance of >/= to 240
dynes-sec-cm-5 (Badesch, et al., 2010; Lourenco, et al., 2012; Vachieiy & Gaine, 2012)
meet the criteria for diagnosis of PAH.
The pathology of PAH involves proliferation of the vessel’s 3 layers: intimal,
medial, and adventitial and encompasses at least three neurohormonal pathways:
endothelin, nitric oxide, and prostacyclin. There is an imbalance of vasodilatation and
vasoconstriction. As such, therapies have been developed that aim at addressing each
pathway (Humbert et al., 2012b). Symptoms such as dyspnea, fatigue, angina, and
syncope often present when the right ventricle (RV) is no longer able to effectively pump
blood against the elevated pulmonary vascular resistance (PVR) (McGoon, et al., 2004).
If left untreated the elevated PVR can lead to RV failure as measured by ejection fracture
(EF) and cardiac index (Cl) and ultimately early death (Champion et al., 2009). Without
effective treatment the median survival of PAH is 2.8 years (Thenappan et al., 2010).
There is currently no cure; thus treatment is aimed at prolonging survival and symptom
mitigation.
The initial vague symptomatology may be attributed to deconditioning, stress, or
anxiety, particularly in women, thus delaying appropriate diagnosis for years (Humbert et
al., 2012a, Traiger, 2007). There is a higher prevalence among women (Pugh & Humes,
2010) with some estimates up to 3 times greater than males (Pugh & Hemnes, 2010).

With the creation of large registries such as the Registry to EValuate Early And Long
term PAH Disease Management (REVEAL) the preponderance of females afflicted with
PAH has become indisputable (Badesche et al., 2010), yet the etiology remains elusive
and seemingly multifactorial (Badesche et al., 2010; Pugh & Hemnes, 2010). The mean
age of diagnosis of 50 (+/-14) years is an age when women are often tasked with being
caregivers, either for children, grandchildren, and/or parents. Nevertheless, there is a
lack of research focusing on the female PAH population, or their perceived SB.
Advanced PAH patients may experience stress related to the uncertainty of their
illness trajectory, the rapidness of the disease progression, the heavy symptom burden,
and the complexity of their critical medication regimen. These factors can combine to
place a patient at higher risk of depression (Matura & Carroll, 2010) and have a heighten
effect on patients’ psychosocial well-being (Khan, 2011). SB is a healthcare priority due
to its impact on the individual, the family unit, and society as a whole.

Statement of Purpose
The purpose of this exploratory study is to describe the perceived SB experience of
advanced PAH patients, and to examine relationships among select demographics (age,
gender, race, education, marital status, living arrangements, and work status), clinical
characteristics (time since diagnosis, medications, time on continuous intravenous therapy,
right atrial pressure, cardiac index, pulmonary vascular resistance, NYHA functional class,
and 6 minute walk test), and SB as measured by the Memorial Symptom Assessment Scale
(Portenoy et al., 1994).

Aims
1. Describe the occurrence and characteristics (frequency, severity and distress) of
perceived symptoms using the Memorial Symptom Assessment Scale (MSAS)
among patients with pulmonary artery hypertension.
2. Examine the relationship between demographics (age, gender, race, education,
marital status, living arrangements, and work status), clinical characteristics (time
since pulmonary arterial hypertension diagnosis, medications, time on continuous IV
prostacyclin if receiving it, New York Heart Association (NYHA) functional class,
right atrial filling pressure (RAP), cardiac index (Cl), pulmonary vascular resistance
(PVR), and 6 minute walk test), healthcare utilization (number of clinic visits,
emergency department visits and hospital length of stay within the previous 6
months), and symptom burden using the Memorial Symptom Assessment Scale
(MSAS) among patients with pulmonary arterial hypertension.

Conceptual Framework
Three domains guide my personal conceptual framework. The first is topical
research, which includes the review and critique of the literature and a review of gaps in
regards to symptom burden in a pulmonary arterial hypertensive population. The second
domain is my theoretical framework of which I have chosen the Revised Symptom
Measurement Model and the Theory of Unpleasant Symptoms. The third domain regards
my personal interest including personal beliefs and experiences. My beliefs system is
affected by my theoretical and political leanings while my experiences include professional
and personal understandings. As a critical care nurse for 15 years most of which was at a

facility world renowned for the treatment of pulmonary hypertension I have come to
understand what it means to live and die with pulmonary hypertension in general. Being
with patients and family members as they traversed the difficult world of critical care I saw
how difficult decisions are in our present healthcare system with its priorities of
technological advancement and postponement of death. The experience of being a recipient
of healthcare for my mother with end stage lung cancer changed my practice dramatically. I
became more empowered to take on an active role in the experience of patients and families
facing difficult healthcare decisions as well as those at the end-of-life. Over time I have seen
the benefits of incorporating palliative care into standard care for patients and families
facing advanced illness.

I__l

Topical research

Theoretical frameworks

|“

Gaps In literature

Symptom burden
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hypertension
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Management
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Figure 1. Madani conceptual framework.
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Implication for Nursing
Assessing the PAH population at a medical center nationally recognized for the
treatment of respiratory diseases will help to elucidate symptom burden perceptions,
possible relationships with demographics, and clinical characteristics. Being able to
optimally measure treatment efficacy for patients beyond the scope of the disease is
necessary to understanding the full impact of an illness, as well as its accompanying
treatment, and is at the center of patient-centered care.
The findings of heavy symptom burden in this population will help to underscore
the need to integrate palliative care into standard care for all advanced PAH patients.
Palliative care goals include assessment and treatment of physical and emotional distress,
communication and decision making with patients and families to achieve patient
centered goals, and coordination of transition care (Hospitals in Pursuit of Excellence,
2012). With early intervention by a multidisciplinary palliative care team, advanced PAH
patients may experience less symptom burden, leading to increased functional status and
QOL.
Clinical nurses are educated and prepared to care for a myriad of different disease
states and levels of care. Healthcare has grown tremendously in technological advances
over the last several decades, yet no concurrent education regarding communication and
end of life care has occurred. Our medical therapies are sometimes extending the dying
process rather than extending quality life. Properly prepared nurses are in a vital position
to help clarify patients’ goals of treatment. Our educational system needs to understand
instruction regarding communication related to difficult decisions universal to nursing.
Not all nurses will go in to specialties such as pediatrics or cardiovascular health, but all

will face the challenge of helping families navigate our healthcare system and be there for
many difficult decisions. Palliative care is a subspecialty in the field of medicine, but for
nursing it is at the center of our profession.
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Chapter II

Background and Review of the Literature
The purpose of this research is to better understand the symptom burden (SB)
experience in pulmonary arterial hypertension (PAH). This chapter and literature review
will provide a critique and synthesis of the current body of knowledge regarding SB in PAH.
It will provide a comprehensive overview of the state-of-the-science research on symptom
burden in pulmonary arterial hypertension. An explanation of the method used to conduct
the literature will be presented in the first section. The second section will examine the
historical context of the symptom experience in PAH, gaps in the science related to
symptom experience in PAH, and the need for further study in this area. In the third section
the theoretical framework, UCSF Symptom Management Conceptual Model (SMCS) is
portrayed to illustrate the concepts and their relationships between each other and within the
model under study in this research. Next my personal conceptual framework is presented
with this study placed within it, followed by theoretical definitions and measurements with
analysis and synthesis of the literature specific to the variables in this study. The purposed
instrument to measure SB will be presented and compared with alternative instruments. In
the final section an analysis and synthesis of the literature specific will be conducted along

with an attempt to describe and understand symptom burden with particular consideration in
an advanced PAH population.
Method of Literature Review
In conducting a thorough review of the literature relating to the symptom experience
in PAH the following steps were followed: an electronic search was conducted among the
following databases; PubMed, CINAHL, Google Scholar, Web of Science, ERIC,
EMBASE, PsychlNFO, and dissertation databases for articles with the following key words
used for the article search strategy: symptom, symptom burden, symptom experience,
symptom cluster, symptom distress, pulmonary hypertension, pulmonary arterial
hypertension, and quality of life.
The list generated was then limited to English language articles relevant to
pulmonary arterial hypertension, symptoms, and quality of life. After the initial electronic
database search, a hand-search was also conducted on citations in the literature found to be
relevant. Abstracts from meetings were included. The literature review contained,
qualitative, descriptive, exploratory, interventional, and evaluation studies, as well as
meeting abstracts, presentations, dissertations, and theses.
The literature synthesis highlights the many issues faced by patients with pulmonary
arterial hypertension. Future research is needed to develop an interdisciplinary approach to
mitigate symptom burden and improve quality of life for patients with PAH.

Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive and chronic disease in
which excessive proliferation of the smooth muscle and vasculopathy lead to constrictive

remodeling of the pulmonary vasculature (Lourenco et al., 2012; Traiger, 2007). There is
currently no cure; thus treatment is aimed at prolonging survival and symptom mitigation.
Pulmonary hypertension (PH) is a general term for a myriad of causative factors
and manifestations of elevated pulmonary pressures but has recently been categorized
according to its etiology (Souza & Simonneau, 2014) (Figure 1). Group 1 is defined as
pulmonary arterial hypertension. Group lb is caused by pulmonary veno-occlusive
disease and pulmonary capillary hemangiomatosis. Group 2 is caused by left-sided heart
disease. Group 3 includes causes related to lung disease or hypoxia. Group 4 is related to
chronic thromboembolic causes, and group 5 includes unclear or multifactorial etiologies.
Hemodynamic diagnostic criteria for pulmonary hypertension is an elevated mean
pulmonary arterial pressure (PCWP) of > 25 mmHg. Pulmonary arterial hypertension is
further differentiated with a normal pulmonary capillary wedge pressure of < 15
(Lourenco et al., 2012; Vachiery & Gaine 2012). The normal pulmonary capillary wedge
pressure differentiates the pulmonary hypertension as pre-capillaiy PH or originating in
the pulmonary vasculature as opposed to PH with PCWP of >15, which may signal postcapillary or pulmonary venous hypertension resulting from left heart disease. This
differentiation is based on the assumption that PCWP is a surrogate marker for left
ventricular end diastolic pressure.

Diagnosis. The differential diagnosis of PAH is difficult and not straightforward
due to the insidious onset and non-specific early symptoms. The initial vague
symptomatology may be attributed to deconditioning, stress or anxiety, particularly in
women, thus delaying appropriate diagnosis for years (Traiger, 2007). An important step
in the differential diagnosis process is elimination of other possible causes. Though some

progress has been made in non invasive technology to diagnosis, a right heart
catheterization remains the gold standard for diagnosis (Vachiery & Gaine, 2012), while
echocardiography remains a useful screening tool. Right heart catheterization can
establish disease severity, test for vasoreactivity, and monitor for treatment effects. Due
to the vague and subtle symptom display many patients are misdiagnosed for years.
Symptoms such as dyspnea, fatigue, angina, and syncope often present when the right
ventricle (RV) is no longer able to effectively pump blood against the elevated
pulmonary vascular resistance (PVR) (McGoon et al., 2004). If left untreated, the
elevated PVR can lead to RV failure as measured by ejection fracture (EF), cardiac index
(Cl), and ultimately early death (Champion et al., 2009). Early symptoms include:
fatigue and dyspnea on exertion. Later symptoms are indicative of right heart failure and
include: edema, ascities, chest pain, palpitations, and syncope (Humbert, Sitbon, &
Chaouat, 2006). Pericardial effusions are an ominous indication of poor prognosis. Even
with the diagnostic and treatment advancements made over the last several decades large
registries are showing proper diagnosis remains prolonged with minimal to no
improvement in the time to diagnosis. It has remained around 2-3 years (Badesch et al.,
2010, Provencher et al., 2005) for the last few decades. Up to 70-80% of patients are in
WHO functional class III or IV upon diagnosis (Frost, Badesch, & Barst, 2011; Vachiery,
& Gain 2012). Without effective treatment the median survival of PAH is 2.8 years
(Thenappan et al., 2010). There is currently no cure; thus treatment is aimed at
prolonging survival and symptom mitigation.
Incidence and Prevalence. A clear picture of pulmonary hypertensions
prevalence and incidence has not been formed due to the rarity of the disease and the

variety of etiologies. The incidence has been projected to be 2.4-7.6 cases/million/year
and prevalence of 15-26 cases/million based on large population studies (Humbert et al.,
2006, Peacock et al., 2007). Under diagnosis is an accepted reality for this population
(Provencher et al., 2005). Prognosis is also difficult to calculate for the reasons listed
above as well as for changing treatments, though newer registries demonstrate
improvement in the last few decades. Three year survival improved from 48%
(McLaughlin et al., 2004) up to 58-72% (McLaughlin & Suissa, 2010). Even with these
improvements in PAH management, progression of the disease is inescapable for a
majority of patients, thus long-term survival remains poor. There is a higher prevalence
among women (Pugh & Humes, 2012) with some estimates up to 3 times that of males
(Gaines & Rubin, 1998; Pugh & Hemnes, 2010). With the creation of large registries
such as REVEAL the preponderance of females afflicted with PAH has become
indisputable (Badesche et al., 2010) yet the etiology remains elusive and seemingly
multifactorial (Badesche et al., 2010; Pugh & Hemnes, 2010). The mean age of diagnosis
is 50 (+/-14) years. This is an age when women are often caregivers, for their children,
grandchildren, and/or parents. Many are still active in the workforce. Nevertheless, there
is a lack of research focusing on die female PAH population or potential symptom
management strategies most effective for women with PAH.
Pathophysiology. Pulmonary arterial hypertension can be hemodynamically
defined as a mean pulmonary arterial pressure (mPAP) greater than or equal to 25 mm
Hg with a concurrent pulmonary capillary wedge pressure (PCWP) of less than or equal
to 15 mm Hg (Badesch et al., 2007) as measured by cardiac catheterization. It can be
clinically defined as a collection of diseases characterized by a continual increase in

pulmonary vascular resistance leading to right ventricular resistance and premature death
(Subias et al., 2010). There are a myriad of causes with the pathophysiology being
multifactorial and opaque. Both genetic and environmental factors have been found to
play a role in the mechanics and function of the pulmonary vasculature. It may occur in
isolation of other disease states, or in conjunction, or as a result of other conditions.
Regardless of the etiology the disease is a serious and progressive illness that leads to
right ventricular failure and eventual death due to the inability of the right heart to
generate enough pressure to pump blood forward into the pulmonary artery. Prognosis is
related to these multifaceted interactions and their impact on the progression of the
obstructive changes in pulmonary microcirculation, as well as the response of the right
ventricle (RV) in working against these increased pressures. Elevated right heart afterload
remains the main cause of heart failure in these patients.
This increased right heart afterload, as measured by PVR, results from
pathophysiological changes in small arteries and pulmonary arterioles. A myriad of
cellular and molecular factors lead to remodeling of the vessel walls via 4 basic
mechanisms: vasoconstriction, cell proliferation, thrombosis, and immune factors (Subias
et al., 2010). Despite a specific known origin, a genetic predisposition has also been
suggested (Chan and Loscalzo, 2008). The resulting imbalance between vasodilatation
and vasoconstriction with cell proliferation is the product of three main neurohormonal
mechanisms. Medical therapy targets these three main neurohormonal pathways: nitric
oxide, endothelin, and prostacyclin (Traiger, 2007, Lourenco et al., 2012), which will be
described in greater detail under the management subheading.

Medical Management. New targeted therapies over the past 2 decades have
improved overall survival with PAH, yet the impact of treatment can be incomplete and
associated with persistent and heavy symptom burden (Swetz et al., 2012). Some patients
can progress to the point of being ineligible or suboptimal for lung transplantation thereby limiting treatment to the most aggressive medical therapeutics such as continuous
intravenous medications. These medications possess a short half life- some as little as 2-5
minutes and must be infused 24/7 via a central line. Abrupt discontinuation could lead to
rapid demise within minutes to hours. As such patients may feel tethered to their
medication and burdened with the critical technical expertise required for the medication
management. Another contributor to the stress of this disease may be the expense of the
drugs, which can cost upwards of ten thousand dollars a month (Baesch, Abman,
Simonneau, Rubin & McLaughlin, 2007). Vasodilation of the pulmonary vasculature
leads to a reduction in right ventricular afterload, reduced workload of the heart,
increased blood flow, and decreased pulmonary arterial pressure. All these factors lead to
improvement in symptoms and exercise tolerance (Vane & Corin, 2003); the ultimate
goals of medical treatment. Medical therapy targets the three main neurohormonal
pathways: nitric oxide, endothelin, and prostacyclin. (Traiger, 2007; Lourenco et al.,
2012).

Nitric Oxide Pathway. Nitric oxide (NO) is a powerful vasodilator produced in
the lung vasculature endothelium by NO synthase (Humbert et al., 2004). It relaxes
vascular smooth muscle by increasing the production of cyclic guanosine monophosphate.
In PAH there is decreased endothelial NO synthase expression. Phosphodiesterase type-5
(PDE-5) is the chief enzyme responsible for the degradation of cyclic guanosine

monophosphate and is abundant in the lung. Inhalation of NO or inhibition of PDE-5,
causes pulmonary vasodilatation (Traiger 2007). Phosphodiesterase inhibitors such as
Sildenafil and Tadalafil are approved by the federal Drug Agency for treatment of PAH
(Lourenco et al., 2012, Kingman & Lombardi 2013).
Endothelin Pathway. Endothelin is a protein with potent vasoconstrictor effects
that induces cell proliferation in vascular smooth muscle and promotes fibrosis and
inflammation Endothelin acts on 2 receptors ETA, which are located on pulmonary
vascular smooth muscle cells and ETB, which are located on pulmonary vascular
endothelial cells and smooth muscle cells. ETA and their activation cause potent
vasoconstriction by increasing the concentration of intracellular calcium. ETB receptors
when activated cause vasodilatation via increased production of prostacyclin and NO in
normal pulmonary vasculature. They also work in the clearance of endothelin. Treatment
for PAH is aimed at blockage of both ETA and ETB receptors or selective blockage of
ETA receptors (Traiger, 2007). Endothelin receptor antagonists have been shown to be
effective in PAH patients with functional class II and III (Lourenco et al., 2012; Kingman
& Lombardi, 2013).
Prostacyclin Pathway. The vascular endothelium produces prostacyclin from
arachidonic acid. Prostacyclin possesses vasodilator, antiproliferative, and antiplatelet
properties. Patients with PAH have been found with low levels of prostacyclin and
decreased expression of prostacyclin synthase. Administration of prostanoid analogs
produces comparable effects as endogenous prostacyclin (Kingman & Lombardi, 2013).
Prostanoids are potent vasodilators that hold anti-thrombotic and anti-proliferative
properties. They cause vasodilatation in the pulmonary vasculature and inhibition of

platelet aggregation via increasing cyclic adenosine monophosphate concentrations
(Hackman & Lackner, 2006; Olschewski, Rose, & Schermuly, 2004). Due to the
complexity of administration and follow up, patients receiving intravenous prostanoid
formulations are usually cared for at experienced centers. Infusion requires a central line
placement with the patient responsible for drug preparation and infusion, as well as
central line management (Lourenco et al., 2012). Side effects include; headache, flushing
and sudden death following abrupt discontinuation (McLaughlin et al., 2009).
Oral treatments such as phosphodiesterase type -5 inhibitors (Sastry, Narasimhan,
Reddy, & Raju, 2004, Zhao, Mason, & Morrell, 2001) and endothelin receptor
antagonists (Channick, Simonneau, & Sitbon, 2001, Rubin, Badesch, & Barst, 2002) have
been effective in patients with mild to moderate PAH. For patients with advanced PAH
unresponsive to conventional therapies intravenous prostacyclin therapy continues to be
one of the most effective treatments (Barst, Rubin, & Long, 1996; Rubin, Mendoza, &
Hood, 1990).
Combination therapy. Research to support combination therapy is new but growing
(Lourenco et al., 2012) as it offers healthcare providers a way to target more than one
neurohormonal pathway in order to improve clinical efficacy and decrease side effects.
Symptom Experience in PAH
New targeted therapies over the past 2 decades have improved overall survival
with PAH, yet the impact of treatment can be incomplete and associated with persistent
and heavy symptom burden (Swetz et al., 2012). Some of these medications possess a
short half-life: as little as 2-5 minutes and must be infused 24/7 via a central line. Abrupt
discontinuation could lead to rapid demise within minutes to hours. Inhaled modalities

may need to be administered up to 25 times a day. As such, patients may feel tethered to
their medication and burdened with the critical technical expertise required for the
medication management.
PAH is a serious disease with unique issues that may have a heighten effect on patients’
psychosocial well-being (Khan, 2011) and place a patient at higher risk of depression
(Matura & Carroll, 2010). Pulmonary arterial hypertension patients on IV medications
may experience stress related to the uncertainty of their illness trajectory, the rapidness of
the disease progression, the heavy symptom burden and the complexity of their critical
medication regimen. SB is a high healthcare priority due to its impact on the individual,
the family unit, and society as a whole.

Theoretical Framework
Revised Symptom Management Model (RSMMj
The Revised Symptom Management Model (Dodd, Janson, Facione, & Froelicher,
2001) is an evidence-based nursing model which underwent revision based on years of
research conducted at UCSF nursing school from the original proposed model put forth by
Lenz, Pugh, Milligan, Gift, and Suppe (1997). This is a comprehensive model describing
the symptom experience and influencing factors. Within the global overlapping and
interconnected nursing domains of person, environment, and health/illness lies the triad of
dimensions of the symptom management model: symptom experience, symptom
management, and outcomes, which also possess interwoven relationships and influences.
Assumptions integral to this model include: (1) the self-reporting of the individual
experiencing the symptom is considered the gold standard, (2) the experience of a symptom
is not a requisite to apply this model. Simply being at risk in enough to warrant intervention

strategies, (3) interpretations of the symptom experience by caregivers of patients unable to
verbalize their symptom experience such a infants are assumed to be correct for assessing
and intervening, (4) the focus of interventions may be the individual, a family, group, or
work environment level, and (5) the process of symptom management is a dynamic, and
influenced by the nursing domains of person, environment, and health/illness.
This research will be examining the RSMM concepts of symptom experience and
symptom status. Specifically, morbidity to assess a relationship between symptom burden,
morbidity, disease progression, and patient demographics as they exist within the nursing
domains of person and disease/illness.
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Figure 2. Revised Symptom Management conceptual model. Adapted from Dodd, Janson,
Facione, & Froelicher, 2001.

The Middle Range Theory of Unpleasant Symptoms
The Theory of Unpleasant Symptoms was first introduced in 1995 and was further
developed and updated in 1997 (Lenz et al., 1997; Lenz & Pugh, 2003). The theory
possesses three major components of the symptom experience. The first contains
influencing factors of situational, psychological, and physiological aspects that impact the
symptom experience. Psychological components such as anxiety and depression have
been shown to impact the experience of a variety of symptoms (Blinderman, Homan,
Billings, Portenoy, & Tennstedt, 2008, Blinderman, Homel, Billings, Tennstedt, &
Portenoy, 2009, Dodd et al., 2001, Ferrari et al., 2013). Situational factors include the
social environment and perceived social support. Variability in patients’ symptom
experience can be attributed to psychological factors such as anxiety and depression and
to situational factors such as social support.
The second component is the symptom experience itself, which contains
dimensions of distress, timing, intensity, and quality of the symptom experience. These
dimensions are assumed to be discreet yet related. The time dimension consists of
frequency, duration, and timing related to certain activities. It is considered the extent to
which the individual is bothered by it. The distress dimension most closely correlated
with symptom burden and most contributes to quality of life. According to this theory it
is how individuals understand the experience and whether symptom mitigation is pursued.
The third component is performance, which speak to consequences of the
symptom experience on three levels: functional status, cognitive functioning, and
physical performance. This holistic theory speaks about the common occurrence of

multiple symptoms manifesting simultaneously and the synergistic effect that may occur.
The experience of symptom is multifaceted, fluid, and dynamic.
This theory has many parallels to the RSMM but RSMM also possesses the
domain of symptom management. This is important for a mid range theory to possesses
as it is less abstract and more purposeful and directional than a grand theory. This helps
to increase the applicability of the theory in clinical practice, as well as measure
outcomes. Early work with this theory was done with the symptoms of dyspnea and
fatigue; two prevalent symptoms in advanced pulmonary arterial hypertension.
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Figure 3. Theory of Unpleasant Symptoms conceptual model. Adapted with permission
from Lenz, E. R., & Pugh, L. C. (2003). The theory o f unpleasant symptoms. In M. J.
Smith & P. R. Lehir, P. R. (Eds.), Middle range theory for nursing. New York, NY:
Springer.

Conceptual Framework
The conceptual framework for this study is heavily influenced by the philosophy
of palliative care. According to the National Consensus for Quality Palliative Care’s 2009
clinical guidelines for quality palliative care (National Consensus Project for Quality
Palliative Care 2009):
The goal of palliative care is to prevent and relieve suffering and to support the
best possible quality of life for patients and their families, regardless of the stage
of the disease or the need for other therapies. Palliative care is both a philosophy
of care and an organized, highly structured system for delivering care. Palliative
care expands traditional disease-model medical treatments to include the goals of
enhancing quality of life for patient and family, optimizing function, helping with
decision-making, and providing opportunities for personal growth. As such, it can
be delivered concurrently with life-prolonging care or as the main focus of care.
Patients with advanced PAH are excellent candidates for the integration of
palliative care into their standard treatment as they face unique multidimensional issues.
In addition to many functional and life limiting symptoms, PAH patients face unique
challenges a few of which include: critical medication management, social isolation, and
financial concerns regarding the cost of medications. A better understanding and measure
of SB in this population could help to evaluate the impact of palliative care services, as
well as help to predict patients that could benefit most from this integration of care.
One fifth of all health care spending in the US is consumed by the costliest 1% of
the population. This group receives most of their care in a hospital setting with
insufficient healthcare coordination (Agency for Healthcare Research and Quality, 2009).
Advanced pulmonary arterial hypertension patients exemplify these concerns. Due to the

cost of their medication regiment they are often refused by hospices and rehabilitation
centers, leaving them in hospital setting unnecessarily for prolonged periods of time.
Palliative care may help to mitigate improper care by assisting with healthcare decisions
and symptom management, as well as providing patient-centered care.

Symptom Burden
Symptom. The word symptom originates from the Greek word symptoma
meaning “anything that has befallen one” (Cleeland, 2007, p. 17). Merriam-Webster
(2012) defines symptom as, “subjective evidence of disease or physical disturbance.”
Gapstur (2007) grouped meaning according to the specialty of the literature and from the
medical literature she derived the definition: “Symptoms are known to be the subjective
evidence of illness or disease that signify a change in normal cellular function” (p. 674).
The concept analysis of symptom management by Fu et al. (2004) found the literature to
conclude a symptom was subjective and experiential, with major dimensions of
symptoms being occurrence, distress, and experience. Within the dimension of symptom
occurrence are frequency and duration.
Burden. Merriam-Webster (2012) reports burden as, “something that is carried:
Load, duty, responsibility, something oppressive or worrisome.” Synonyms listed are:
load, encumber, freight, lade, laden, lumber, saddle, and weight. In the psychology
literature Possemato (2010) referred to disease burden in Veterans as, the aggregate of
medically diagnosed conditions. The mother of the writer of this paper used the phrase
“cross to bear” that conjures up a rather frightful image to convey her idea of a heavy

burden or onerous lot in life. In looking at the concept it is important to note burden
consistently possesses implicit negative connotations in the literature (Cleeland, 2007).
The theory of unpleasant symptoms (Lenz et al., 1997) describes distress, as the
extent to which a person is disturbed by a symptom and suggests its perception is
influential in whether a person seeks to continue aggressive treatment or palliation.
Distress is also the element with the greatest impact on quality of life. Distress, worry,
and oppression are analogous in the symptom experience.
Symptom Burden. Symptom Burden is a phenomena often associated with
chronic and terminal disease, particularly cancer (Gaspur, 2007). Other disease
progressions that have attempted to understand SB include, hemodialysis (Weisbord et al.,
2003); COPD (Klinkenberge, Willems, van der Wal, & Deeg, 2004), heart disease (Ruo
et al., 2004), chronic critical illness (Nelson et al., 2004), inflammatory bowel disease
(Farrell & Savage, 2010), and diabetes (Ludman et al., 2004). Though there is recent
work looking at symptoms of PAH (Ferrari et al., 2013), there is a dearth of information
looking specifically at the burden of living with this advanced disease and its treatment.
Gapstur (2007) conducted a concept analysis of symptom burden with an
oncologic focus, in which she found a consistent report of the adverse effects of
symptoms on quality of life (QOL), physical, social, and psychological functioning, as
well as cost of treatments and hospitalizations. The definition produced from her concept
analysis is “the subjective, quantifiable prevalence, frequency, and severity of symptoms
that place a physiologic burden on patients and may produce multiple negative physical,
psychological, and emotional patient responses” (p. 667). Fu, McDaniel, and Rhodes
(2007) in the development of the Symptom Experience Index (SEI), defined SB as the

extent of physiological and psychological suffering resulting from a person’s response to
symptom manifestation. Gough, Smith, Ross, Riley, and Judson (2011) reported SB in a
sarcoma population as the experience of symptoms resulting from the disease or its
accompanying treatments. Cleeland (2007) spoke to the implicit negative connotations
of symptoms in general, terming SB as a collective imposition of distress on a person.
The self-regulation theory (Leventhal & Johnson, 1983) differentiates the
experience of symptoms into the incidence of a symptom and the emotional distress
associated with it. The latter aspect could be considered SB. The suffering arising from
symptom experience is influenced by the degree of perceived departure from one’s
baseline function, sensation, appearance, and the individual analysis of the value of these
events (Rhodes et al., 2000). Thus symptom distress is the appraisal of the distress and
degree of burden.
Gapstur (2007) differentiates symptom burden from distress, but by only a miniscule
margin. Untangling the nuances may not be time well spent. The literature conflates
symptom distress and burden in many disease states (Cleeland, 2007; Farrell & Savage,
2010; Fu et al., 2004; 2007). Burden by its definition implies distress, thus suffering is
implicit in the symptom burden experience. Instruments measuring SB measure distress
and or severity, such as the Condensed Memorial Symptom Assessment Scale (Weigand
& Kalowes, 2007), Symptom Experience Index (Fu et al., 2007), Adapted Symptom
Distress scale (Rhodes et al., 2000), and Memorial Symptom Assessment Scale (Joyce,
Akbar, & Khan, 2008, Portenoy et al., 1994). The literature supports the terms symptom
distress, burden, and severity as equally measuring the negative impact of symptom

experience. Now the focus should be on instruments to optimally measure and mitigate
negative consequences of symptom experience.
Critical Attributes of Symptom Burden
Subjective Perception/Appraisal of Distress. Symptom burden is the individual
appraisal and response to the experience of a symptom and possible distress. Core
aspects of the appraisal include, perception, evaluation of the meaning of the experience,
and response (Farrell & Savage, 2010; Fu et al., 2004; 2007). Cleeland (2007) described
SB as the patient’s summative perception of the impact and severity of symptoms from
tumor or treatment burden, and contrasted the individual’s subjective observance and
report of a symptom, against “signs” of disease, which are empirically measureable.
Symptoms are a subjective experience that may be amplified by the perception of the
symptom(s) infringement upon the patient’s lifestyle and relationships, as well as their
perceived ideal vision of themselves or role attainment before illness (Lazarus &
Folkman, 1984). One of the constructs in the cognitive adaption model is appraisal,
which can be described as how a person understands an experience. It suggests people go
thru a primary and a secondary cognitive appraisal in response to a stressor. Initially a
person will assess the relevance and threat of a situation. The second step is more
complex but can be summarized as an evaluation of one’s coping strategy options
(Lazarus & Folkman, 1984). A patient’s perception of their SB is determined by their
appraisal of impact on their lives and quality of reserves to cope (Newness, 2011). This
aspect of stress appraisal is integral to the symptom burden experience.
Dynamic. Symptom burden is a fluid phenomena that ebbs and flows according to
the multidimensional factors’ interactions and their relationship of continuous reciprocity

(Dodd et al., 2001). Examples include: the context of the symptom, the patients’ disease
progression, treatment (if any), as well as the physiological, psychological, and social
response to both. (Dodd et al., 2001; Fu et al., 2004; 2007; Gapstur, 2007). According to
the theory of unpleasant symptoms the expression of symptoms may differ in regards to
the intensity, quantity of associated distress, timing, and quality (Farrell & Savage, 2010).
Multidimensional. Symptom burden has a myriad of contributing, initiating, and
exacerbating factors. Subsets of multidimensional include: physiological, psychological,
and social (Dodd et al., 2001; Gapstur, 2007). Physiological dimensions can be further
broken down into frequency, prevalence, and intensity (Farrell & Savage, 2010; Gapstur,
2007; Lenz & Pugh, 2003). Social dimension can be affected by a person’s age, gender,
culture, values, education, health knowledge, disease, treatments, beliefs, and past
experiences (Fu et al., 2004). There was divergence in the literature with some authors
looking at the three dimensions and others only counting the number of symptoms as a
representation of multidimensionality (Gapstur, 2007). For SB to be considered
multidimensional it must possess more than a single dimension of the symptom
experience.
The Theory of Unpleasant Symptoms (Lenz et al., 1997) is comprised of three major
concepts: the experience of the symptom, influencing factors, and consequences of the
experience. Every symptom is a multidimensional occurrence that may ensue in
isolation or in combination with other symptoms from a disease or its treatment. Aspects
of the symptom experience are timing, intensity, quality, and distress. Influencing factors
on the symptom experience are categorized as physiological, psychological, and
situational which is akin to social factors.

The largest study to date looking at the impact of PAH on patients’ lives found three
overall dimensions of symptom impact: physical, social, and psychological. As the
patients functional status increased so did the burden of their symptoms (Ferrari et al.,
2013). Two distinguishing aspects particular to PAH patients is the significant burden
imposed by the inconvenience and side effects of the medication regimen (McKenna et
al., 2006), and the social isolation associated with an orphan disease and a misinformed
public (Ferrari et al., 2013; Wryobeck, Lippo, McLaughlin, Riba, & Rubenfire, 2007).
Empirical Referents for Symptom Burden
Empirical referents measuring critical attributes of SB can be differentiated
according to the attribute. For perception of distress the referents include: evaluation,
degree, or impact of distress of the symptom experience. For the attribute dynamic the
referents are: frequency, intensity, quality, and timing. The attribute multidimensional
has referents of physical, psychological and social impact on daily living such a
functional ability and status.
When SB is not adequately managed patients tend to come into the emergency room for
assistance in managing their symptoms and may be admitted to the hospital. Thus ED
visits and hospital admissions with diagnosis, length of stay, pain scale, and prescribed
medication regimen would be empirical referents.

Theoretical Definitions and Measurements
Demographics. Demographic data will be collected by a self-report and will
include: gender, age, ethnicity, marital status, education, and employment (Appendix B).

These are important concepts as purported by the RMCM model and fall under the
dimension of person, and environment.
Gender. The initial vague symptomatology may be attributed to deconditioning,
stress or anxiety, particularly in women, thus delaying appropriate diagnosis for years
(Traiger, 2007). There is a higher prevalence among women, with some estimates up to 3
times greater odds (Pugh & Hemnes, 2010). With the creation of large registries such as
REVEAL the preponderance of females afflicted with PAH has become indisputable
(Badesch et al., 2010), yet the etiology remains elusive and seemingly multifactorial.
Nevertheless, there is a lack of research focusing on the female PAH population or
potential symptom management strategies most effective for women with PAH.
Age. The mean age of diagnosis in PAH is 50 (+/-14) years (Badesch et al.,
2010). This is an age when people are often caregivers, for their children, grandchildren,
and/or parents. Many are still active in the workforce.
Ethnicity, marital status, education, and employment have been measured in
previous studies in the PAH population along with quality of life (Badesch et al., 2010,
Batal et al., 2011, Ferrari et al., 2013, Hwang, Howie-Esquivel, Fleischmann, Stotts, &
Dracup, 2012; Matura & Carroll, 2010, Matura et al., 2012b) and symptom burden
studies with other medical diagnoses (Blinderman et al., 2008; 2009, Cleeland, 2007; Fu
et al., 2004).
Clinical Characteristics. Clinical characteristics fall within the domain of Health
and Illness in the RMSM model and impact the symptom experience.
NYHA Functional Class. The New York Heart Association’s nomenclature for
functional classification was first proposed in 1928 and has since been revised several

times with the most recent revision in 1994. The status has been shown to be associated
with disease progression (Humbert, Sitbon, & Simonneau et al., 2004, New York Heart
Association, 1964), serves as a measure of disease severity as a measure of exercise
intolerance, and is used as an approximate measure of the provider’s opinion of the
patients’ functional status in clinical trials.
Class I refers to patients with cardiac disease but without the resulting
limitations of physical activity. Ordinary physical activity does not cause undue
fatigue, palpitations, dyspnea, or angina pain. Class II refers to patients who have
cardiac disease resulting in slight limitations of physical activity. They are
comfortable at rest. Ordinary physical activity results in fatigue, palpitations, dyspnea,
or angina pain. Class III patients have cardiac disease that results in marked limitation
of physical activity. They are comfortable at rest. Less than ordinary physical activity
causes fatigue, palpitations, dyspnea or angina pain.
Class IV patients with cardiac disease results in inability to carry on any physical
activity without discomfort. Symptoms of cardiac insufficiency or of the angina
syndrome may be present even at rest. If any physical activity is undertaken,
discomfort is increased (New York Heart Association, 1964).
Six minute walk test. The six-minute walk test is a noninvasive and simple test
measuring the distance a person is able to walk within 6 minutes. It has been found to
correlate well with functional exercise capacity, disease progression, mortality, and is an
established outcome in clinical trials (Humbert, Sitbon, & Simonneau et al., 2004). The
general cut off for a healthy walking distance is considered to be greater than 333 meters
(Humbert et al., 2012a).

Right atrial pressure. The right atrial pressure, also known as central venous
pressure is a measure of the blood in the thoracic vena cava near the right atrium of the
heart. It is a surrogate for preload or the amount of blood returning to the heart and the
ability of the heart to pump the blood forward. It can be measured via echocardiography,
heart catheterization, or with a central line and bedside monitoring. (Subias, Mir, &
Suberviola, 2010). The tip of the catheter is attached to a transducer, which reads the
pressure being exerted by the blood inside the right atrium. The transducer produces a
waveform that consists of a, c, and v waveforms. The a wave represents atrium
contraction, the c wave represents tricuspid valve closure, and the v wave represents
ventricular contraction which causes the valve to bulge into the atrium.
Right atrial pressure is regulated by a balance between the ability of the heart to move
blood out of the right heart and through the left heart into the systemic circulation, as well
as the amount of blood returning to the heart from the systemic circulation. The normal
range of CVP is 0-5 mmHg. Possible causes of an elevated CVP include an inability to
fill adequately due to such causes as congestive heart failure, hypervolemia, cardiac
tamponade, or vasoconstriction, which affects the ability of the heart to empty its
chambers. Decreased pressure may be indicative of hypervolemia (Urden, Lough, &
Stacy, 2010). Right atrial pressure is a vital indictor of right heart function and disease
progression in PAH (Humbert et al., 2004).
Cardiac index. Cardiac output represents the amount of blood volume pumped
out by a ventricle. Cardiac output is a function of heart rate per minute multiplied by the
volume of blood pumped by the heart with each contraction, i.e. stoke volume (ml/beat),
e.g. CO = HR x SV. In comparison, cardiac index is the volume of blood pumped by the

heart per minute divided by the individual’s body surface area. It is considered to be a
more accurate measurement since it is based on an individual’s height and weight.
Normal Cl range is 2.2-4.0 L/min/ m2 (Urden et al., 2010), and is used as an indicator of
overall cardiac function, as well as disease progression in PAH (Humbert et al., 2004).
Pulmonary vascular resistance. PVR is a measure of the right heart’s afterload
or mean pressure difference across the pulmonary vascular bed, divided by blood flow.
Clinically, this value represents resistance that the right ventricule must overcome in the
pulmonary arteries and arterioles in order to eject the blood volume and move the blood
volume forward. As the pressure in the pulmonary vasculature increases the output from
the right ventricle decreases. It is usually measured in dynes/sec/cm-5, with normal
pressures ranging from 100 - 250 dynes/sec/cm-5 (Urden et al., 2010). In the left side of
the heart the left ventricle must pump against the pressure in the systemic circulation or
aorta and is referred to as system vascular resistance or SVR. Increased afterload
remains a main measurement of heart failure in PAH (Humbert et al., 2004; Subias et al.,
2010,).

Months Since Diagnosis and Months on IV or SQ therapy. The length of time a
patient has been living with PAH and receiving more advanced medical therapy may be
relevant to their symptom burden.
Symptom Burden
The instrument to measure psychological and physical symptom burden for the
study was the Memorial Symptom Assessment Scale (MSAS) (Portenoy et al., 1994). The
MSAS is a patient self-reported instrument to assess the occurrence, characteristics, and
extent of symptom burden. Twenty-six physical symptoms and six psychological symptoms
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are measured on 4 or 5-point Likert scales assessing how often, severe, and how much
distress is associated with each symptom. This measure includes: the overall number of
symptoms experienced, the average total score of each symptom across the three dimensions
of frequency, severity and associated distress (MSAS- Total), and three main symptom
burden subscales: physical symptom distress subscale (PHYS), psychological symptom
distress subscale (PSYCH), and the global distress scale (GDI). The mean score of six
psychological symptoms is the PSYCH subscale score: worrying, feeling sad, feeling
nervous, difficulty sleeping, feeling irritable, and difficulty concentrating. The PHYS
subscale is the mean of the 26 physical symptoms. The GDI subscale is purported to be a
gross measure of the perceived global symptom distress and is considered the most
clinically useful measure of the MSAS (Portenoy et al., 1994). It is comprised of the
frequency scores the following four psychological symptoms: worrying, feeling sad,
feeling nervous, and feeling irritable, and the distress scores from the following six
physical symptoms: pain, lack of energy, lack of appetite, constipation, feeling drowsy
and dry mouth. The MSAS and it subscales have been used to study the effects of
symptoms as a predictor of survival (Chang, 2004), while the total number of symptoms
experienced on the MSAS has correlated with a spiritualty measurement tool (Peterman,
2001).

In the MSAS’s initial psychometric analysis two major factors related to
meaningful grouping of symptoms emerged. One group, named PSYCH, contains 6
symptoms relating to psychological status. It can be divided into a subgroup with 4
symptoms that are emotional in type named EMOT, and a subgroup termed CONC with
2 symptoms: difficulty sleeping and concentrating. In this study the six symptoms of the

PSYCH subscale were used without teasing out the smaller EMOT and CONC subgroups
due to their small number. Another larger group, named PHYS H, has 12 frequent
physical symptoms. The third and final group is named PHYS L, which contains 15
physical symptoms that occur with less frequency compared to PHYS H. In this study
the PHYS subscale used to capture all 26 physical symptoms. The 12 frequent physical
symptoms comprising the PHYS H subscale are considered the MSAS-PHYS subscale
(table 6). The MSAS-Total subscale is the average of the dimensions scores for each
symptom. This score is not considered to be a strong clinical indicator of symptom
burden (Chang, et al., 2004; Portenoy, et al., 1994).
The initial population the MSAS was normed with was an oncology population. It
has since been psychometrically tested in varying chronic illness and cultures (Chang et
al., 2004; Weisbord et al., 2003). The MSAS-SF has been utilized most widely in patients
with cancer and AIDS, where it has been shown to have good reliability and validity
(Portenoy et al., 1994) (Weisbord et al., 2003). The Cronbach alpha coefficients for internal
reliability were 0.882 for the PHYS H. The coefficient for PSYCH grouping was 0.835.
The coefficients for group PHYS L was lower at 0.580. Reliability will be computed with
the study sample prior to data analysis. Recently, the MSAS has been shown to be a valid
and reliable measure of symptom burden in two similar population; congestive heart failure
and chronic obstructive pulmonary disease (Blinderman et al., 2008; 2009).
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Table 2
Components o f Memorial Symptom Assessment Scale (MSAS) Subscales: Psychological (PSYCH)
Symptoms, Physical (PHYS) Symptoms, and Global Distress Index (GDI)
Subwale
MSAS PSYCH

Symptom
Difficulty concentrating
Feeling sad
Feeling nervous
Difficulty sleeping
Feeling irritable
Worrying

MSASPHYS
Pain
Lack of energy
Nausea
Feeling drowsy
Feeling bloated
Vomiting
Lack of appetite
Dizziness
Changes in the way food tastes
Weight loss
Constipation
MSAS GDI
Average frequency wore of the following psychological symptoms
Feeling nervous
Feeling sad
Worrying
Feeling irritable
Average distress wore of the following physical symptoms
Pain
Lack of energy
Lack of appetite
Feeling drowsy
Constipation
Note. Portenoy, R. K., Thaler, H. T., Komblith, A. B., Lepore J. M., Friedlander-Klar,
H., Kiyasu,... Norton, L. (1994). The Memorial Symptom Assessment Scale: An
instrument for die evaluation of symptom prevalence, characteristics and distress.
European Journal o f Cancer, 30A(9), 1326-1336.

Healthcare Utilization Measurements
The sickest 10% of the US population accounts for more than half of its
healthcare expenditures (Zuvekas, 2007 #132). One fifth of all health care spending in the
US is consumed by the costliest 1% of the population. This group receives most of their
care in a hospital setting with insufficient healthcare coordination (Agency for
Healthcare Research and Quality, 2009). Advanced pulmonary arterial hypertension
patients exemplify these concerns. Due to the cost of their medication regiment they are
often refused by hospices and rehabilitation centers, leaving them in hospital setting for
prolonged periods of time unnecessarily. Insufficient outpatient support and coordination
of care can lead to misuse of acute care services. Interdisciplinary services such as
palliative care may help to mitigate improper care by assisting with transitions of care,
symptom management, and healthcare decisions by establishing patient and familycentered goals and working to help the patient achieve those goals. Quality palliative care
(PC) can benefit the patient and their family foremost, but may also help to achieve the
Institute of Healthcare Improvement’s (IHI) tripe aim of: improving patients’ experiences
of care (including quality and satisfaction), improving the health of populations, and
reducing the per capita cost of healthcare (Berwick, Nolan, & Whittington, 2008).
Pulmonary Hypertension Clinic Visits. Patients living with PAH are usually
seen by their PH specialist every three to six months depending on the stability of their
disease progression and medical management. Non-pulmonary clinic visits were not
recorded. This was determined by the name of the attending for the visit listed in the
electronic medical record. Only pulmonary specialist visits were recorded. The number of

clinic visits in a six-month visit could be a red flag for providers to take a closer look at
patient’s symptom burden and possible need for initiating a palliative care consult.
Emergency Department Visit and Hospital LOS related to PAH. Both of these
metrics were recorded as additional measures of healthcare utilization within the previous
six-month time frame.
Literature Analysis and Synthesis
As noted previously studies have shown incongruence between HRQOL measures
and symptomology. Though HRQOL measures have been shown to be prognostic for
survival they also remain too generic for symptom response to medical management, thus
a better understanding of the concept of SB may help to more accurately measure patient
reported outcomes, and a more specific symptom assessment is needed to elucidate the
symptom experience of patients and understand medication side effects, as well as
treatment response.
HRQOL measures emphasize physiological aspects of QOL regarding treatment that may
or may not improve functional performance, symptoms or physical dysfunction, however
anxiety and depression are significant players in the QOL measurement. Despite the
awareness that QOL is a subjective and dynamic concept the need for empirical
measurement overrides this discussion of its merit to measure such things. Previous
studies in PAH have pointed out the shortcomings of the Cambridge Pulmonary
Hypertension Outcome Review (CAMPHOR) to adequately assess symptomology
(Matura et al., 2014). The CAMPHOR is the initial measure for assessing patientreported symptoms, functioning and QOL specifically for pulmonary hypertension
(Gomberg-Maitland et al., 2008). This instrument was shown to be reliable and valid yet
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the instrument itself does not allow for answers to be on a continuum and may miss out
on more detailed information (Matura et al., 2014). Respondents mostly may choose only
dichotomous answer choices; true/false or yes/no answers. There is also no measure of
the associated distress from the symptoms, which is a vital aspect of the Revised
Symptom Management Model (Dodd et al., 2001).
In a study looking at predictors of QOL in an idiopathic PAH population, patients
with less functional ability, had decreased physical health status, HRQOL, and increased
psychological distress. HRQOL predictors included symptom and activity totals on the
US CAMPHOR, role emotional on the SF-36, depression scores on the POMS,
employment status, and oxygen use (Matura et al., 2012b). This study underscores the
need for nursing to focus on symptoms and response to treatment in caring for PAH
patients.
Two reviews of the literature of the human response to and psychological aspects
of PAH described the need for a better understanding of the prevalence and impact of
symptoms, both psychological and physical, experienced by PAH patients in order to
develop effective interventions to be developed and tested. (Matura & Carroll, 2010;
Wryobeck et al., 2007).
Although there has been limited qualitative work done in this population, two qualitative
studies specifically on the patient’s experience of PAH were found. The samples were
well matched with the large registries on PAH. Khan (2011) interviewed a majority of
functional class three participants. Interviews were conducted via phone as a means to
encourage responses “without much thought” thus providing a more neutral answer. Two
overriding themes emerged from this work, “holding back” and “redefining life”. The

predominant issues were fear of breathlessness and the uncertainty of the disease
trajectory. Breathlessness was related to either “taking things slowly” or a “fear of
blacking out”. Medication issues tended to reside within both themes, with the aspects of
activity limitation falling under holding back and practical medical necessities such as
maintaining a central line and oxygen therapy related to the redefining life theme.
Adjustment to medication regimen fell under redefining life along with the stoicism
needed to “accepted their medical situation”. Flattery, Pinson, Savage, and Salyer (2004)
used a phenomenological approach to examine the lived experience of PAH with a
sample of 1l.Two overarching themes emerged: uncertainty of the disease progression
and other aspects of the disease, as well as learning to cope with the illness.
The largest study to date looking at the global impact of PAH on patient and
caregiver’s lives was conducted in 5 European Union countries (Ferrari et al., 2013). The
first phase of the study was qualitative and consisted of 40 patient and caregiver
interviews; 25 patients and 15 caregivers. The second phase was a quantitative
questionnaire distributed to 455 individuals; 326 patients with PAH and 129 care givers
of patients with PAH. The aim of this large-scale study was to provide new
understanding(s) of the global impact of PAH on patients and care givers beyond the
clinical definition of the physical weight of the disease, which had not been
comprehensively researched The four main areas inspected included: the physical and
practical impact of PAH, the emotional impact, the financial impact, and information
needs and requirements to better understand PAH patients’ and care givers’ experience of
living with PAH. As the patients functional status increased so did the encumbrance of
their symptoms. Results underscore the need to offer comprehensive care that assesses

emotional and social well-being, as well as physical symptoms and understanding these
needs increase as functional class increases. Educational provisions regarding PAH
should include financial, social, and emotional aspects of the disease and its treatment.
These findings point to the importance of incorporating palliative care into the standard
care of PAH patients, especially as they progress to functional class III and IV. Three
dynamic dimensions of symptom burden in PAH emerged from this study. The physical
dimension consists of functional class. The social dimension speaks to the isolation of
having an orphan disease whose physical presentation can often belie the true limitations
of the disease. This often creates a lack of understanding and compassion from those
close to the patient, as well as the community at large. The third dimension of symptom
burden in PAH is psychological, which is impacted by emotional and financial situations,
as well as social aspects of living with the illness. Both patients and caregivers felt
healthcare professionals provided inadequate information to them, with patient
organizations as the major source of information and support. The present gap in care
delivery is highlighted by this study. Palliative care could assist families understand and
work through difficult healthcare decisions to ensure they are in alignment with their
family’s goals of care.
Standard QOL measurements, as well as those particular to chronic lung or heart
disease do not properly reveal the clinical status or prognosis of persons with PAH
(Rubenfire et al., 2009). Other pulmonary disease metrics do not apply to PAH because it
is a circulation problem not an alveolar problem. Presently there is no adequate measure
of the symptom experience in PAH.

Summary
Literature on PAH speaks to the burden of living with the disease and its
treatment (Ferrari, et al., 2013; Khan, 2011; Matura et al., 2014a; Oudiz, 2012).
Distinguishing aspects particular to PAH patients are the significant onus imposed by the
inconvenience and side effects of the medication regimen, the lack of wider
understanding regarding the disease which often heightens social isolation, and financial
concerns of the medication (Ferrari, et al., 2013; Khan, 2011; Matura et al., 2006;
McDonough & Carroll, 2012; Oudiz, 2012).
Cleeland (2007) suggested symptom burden could have specific attributes specific
to different disease trajectories. Patients with PAH face unique multidimensional issues,
yet no measure has been developed to adequately measure PRO specific to this
population. This study will be a step towards achieving this goal.
Symptom burden can be considered analogous to carrying a cross. It is the weight
of the symptom experience. The appraisal of onus is subjective and experiential on the
patient’s part, yet a measure of distress is implicit in the symptom burden experience.
Being able to optimally measure symptom treatment efficacy for patients beyond the
scope of the disease is vital to understanding the full impact of an illness, as well as its
accompanying treatment, and is at the center of patient-centered care.
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CHAPTER III
Methodology
The purpose of this study was to examine the relationship between demographics,
clinical characteristics, and symptom burden (SB) in a pulmonary arterial hypertensive
(PAH) population. Additionally, it will describe a sample of people living with PAH who
have not previously been studied regarding SB and healthcare utilization. This chapter offers
a detailed description of the research design, sampling, instrumentation, and analytic
techniques. The protection of human subjects is also discussed.
Aims
1. Describe the occurrence and characteristics (frequency, severity and distress)
of perceived symptoms using the Memorial Symptom Assessment Scale
(MSAS) among patients with pulmonary artery hypertension.
2. Examine the relationship between demographics (age, gender, race, education,
marital status, living arrangements, and work status), clinical characteristics
(time since PAH diagnosis, medications, time receiving IV prostacycline if
receiving it, New York Heart Association (NYHA) function class, right atrial
pressure (RAP), cardiac index (Cl), pulmonary vascular resistance (PVR), and 6
minute walk test), healthcare utilization patterns (number of clinic visits,
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emergency department visits and hospital length of stay within the previous 6
months), and symptom burden using the Memorial Symptom Assessment
Scale (MSAS) among patients with pulmonary arterial hypertension.

Research Design
A descriptive cross-sectional, correlational design was used for this study. The
purpose of a descriptive correlational design is to examine the direction and magnitude of
relationships that may exist in particular situations (Polit, 2010). A descriptive correlational
study is specified as a study conducted in a naturalistic setting without any attempt to
manipulate, control, or introduce something new to the setting (Kerlinger & Lee, 2000). It is
also useful to obtain information in areas in which minimal or no research has been
previously done. This method is optimal for obtaining the specific aims identified by
exploring the relationship between symptom burden, demographics, and clinical
characteristics, as they presently exist.

Setting and Sample
A consecutive convenience (purposive) sample of adult (>18 years old)
pulmonary arterial hypertension (PAH) patients were recruited from a tertiary, academic
hospital system, which serves as a national referral center for pulmonary hypertension
patients in the southwest United States over a 6-month period. Consecutive sampling plan
was employed due to its superior approach in mitigating sample bias. By attempting to
recruit all members of an accessible population, bias risk can be deeply reduced (Polit &
Beck, 2012). Specialists at this tertiary academic institution were encouraged to offer
participation to all qualifying patients. Eligible patients include patients diagnosed with

PAH, >18 years of age, and able to speak and read English. Exclusion criteria include,
participants with a serious or unstable medical or psychological condition that in the
opinion of the principal investigator would compromise participation in the study or had
a coexisting illness unrelated to PAH that may confound the assessment and non-English
speaking.
Anticipated refusal rate was 10%. This correlates with a typical expected drop out
rate (Polit & Beck, 2012), and intrinsic motivation to participate in research that may
benefit others living with the same disease. People with orphan disease may have stronger
ties or a sense of responsibility to help improve the lives of others with their disease. Due to
the smaller number of people afflicted with PAH they may possess a greater sense of
collaboration or duty. The anticipated drop out rate is 10% due to SOB or loss of interest
during the expected 10 minutes needed to complete the survey.

Power Analysis
The necessary sample size for this study was determined by calculating the effect
size, the desired power, and an acceptable significance level. In order to determine
significance of statistical results an adequate sample size must be utilized to minimize the
possibility of making a type II error. With Pearson correlations the estimated value of
estimate size is p, the population correlation coefficient (Polit & Beck, 2012). With an
estimated population correlation of .30 (medium effect size), a power level of .80, and alpha
of 0.5 a sample of 85 was needed to avoid a type II error.

Data Collection Procedures
Subject Recruitment and Enrollment
The PAH specialist RN was asked to identify eligible patients as they presented for
routine office visits or if they were inpatient at the hospital over a seven month period;
October 2013 through April 2014. Pulmonary arterial hypertension patients are seen by their
pulmonologist every 3 to 6 months if they are stable on their present treatment, more often if
they are not. The PAH specialist nurse recruited participants at the time of their routine
scheduled clinic visit. She provided all potential participants with a recruitment flyer as part
of clinic check in at the time of their scheduled clinic visit. She assessed for interest to
participate after the patient had time to read the flyer in the waiting area or clinic room.
Written informed consent from each participant was obtained after explaining and
discussing the study by the PAH specialist nurse or primary investigator (Appendix A).
Data Collection Protocol
Interested participants were provided with an information letter on the study that
included: (a) an overview of the study, (b) name and phone number of the principal
investigator, (c) information regarding the right to refuse participation by not completing the
questionnaires, (d) their ability to withdraw from the study at anytime, (e) a guarantee of
confidentiality, (f) a UCSDIRB approved letter of consent (Appendix A), and a UCSDIRB
approved Request for HIPPA waiver to access medical records. Those willing to participate
were provided a packet containing a consent form to participate in the study and to access
their medical record, an Experimental Subject’s Bill of Rights, and a survey comprised of
demographic, and healthcare utilization questions (Appendix B) and the MSAS (Appendix
C) during their visit. The estimated time to complete the packet was 10 minutes. The packet

and signed consents were completed by the participants and collected during the same clinic
visit by the PAH specialist nurse or PI. The primary investigator, through chart review,
collected clinical characteristics data and healthcare utilization information such as the
number of emergency department visits, hospitalizations and clinical visits related to their
PAH diagnosis in the previous six months (Appendix D). Electronic data are stored on a
password-protected computer and written information related to this study is being kept in a
locked office at UCSD.

Variables/Instruments
Demographics
Data were collected on the following selected demographic items: age, gender, race,
education, marital status, living arrangements, and work status (Appendix B).
Clinical Characteristics
Clinical data to be collected include, time since PAH diagnosis, PAH related
medications, years on IV prostacycline if receiving it, New York Heart Association (NYHA)
functional class, central venous pressure (CVP), cardiac index (Cl), pulmonary vascular
resistance (PVR), and 6 minute walk test (Appendix D).
Healthcare Utilization Pattern
Healthcare Utilization was measured by the number of emergency department visits,
hospitalizations, and clinical visits the patient had in the previous 6 months related to their
PAH treatment. Healthcare utilization related to other diagnosis was not recorded. These
data were collected on both the patient and investigator measure to help identify patients
who needed a more detailed chart review and to help mitigate missing data.
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Memorial Symptom Assessment Scale (MSAS)
The instrument to measure psychological and physical symptom burden for the
study was the Memorial Symptom Assessment Scale (Portenoy et al., 1994). The MSAS
was developed to provide a multidimensional picture of prevalent symptoms in patients
with diverse types of cancer. Since its inception it has been adapted and used in other
chronic illness such as HIV, congestive heart failure, and chronic obstructive pulmonary
disease (Blinderman et al., 2008; 2009, Selwyn et al., 1999) as well as clinical trials
(Chang et al., 2004). It is a self-report measure, which includes 32 symptoms common to
cancer and three dimensions relevant to symptom evaluation: the severity of the symptom
experience, the frequency with which the symptom occurs and, the distress associated
with the symptom. For six symptoms in which frequency was not relevant, only severity
and distress are measured. Separate four or five-point Likert scales were created for the
three dimensions for all the symptoms. The average of each symptom score across the
three dimensions is referred to as the MSAS-Total score. The total overall number of
symptoms reported by an individual is also considered to be clinically relevant. The three
subscales capable of being be calculated are: physical symptom distress subscale (PHYS),
psychological symptom distress subscale (PSYCH), and the global distress scale (GDI).
The mean score of six psychological symptoms is the PHYS score. The mean score of 12
prevalent physical symptoms constitutes the PHYS subscale. The mean distress score of six
physical symptoms and frequency scores four psychological symptoms form the GDI score.
The range of subscale scores is 0 (minimal distress) to 4 (maximal distress). The MSAS has
been utilized widely in patients with chronic illness, where it has been shown to have good
psychometric properties of reliability and validity (Blinderman, et al., 2008; 2009; Chang, et

al., 2004; Portenoy, et al., 1994; Weisbord, et al.,2003). The Cronbach’s alpha for the
physical subscale is 0.88, and for the psychological subscale is 0.84. Reliability was tested
with the study sample prior to data analysis. Cronbach’s Alpha coefficients for PSYCH,
PHYS, GDI subscales were .947, .920, and .821 respectively.

Data Analysis
Data were screened for distribution patterns and outliers. Missing data and outliers
were individually checked in the electronic medical record and on data collection forms.
Descriptive data were reviewed on all variables with scatterplot diagrams, mean, median,
and mode for continuous variables and frequencies for ordinal or categorical data. Data
were checked for meeting assumptions of normality, linearity, and homogeneity of
variance before conducting a Person’s correlation coefficient. Initial bivariate correlation
was conducted on all key variables before conducting other analyses.
Data are described as mean +/- standard deviation for normally distributed variables,
as median with minimal and maximal values for skewed variables, and as percentages for
categorical variables. To explore factors associated with overall symptom burden, the global
distress index (GDI) score was considered the primary outcome for all bivariate analyses. In
bivariate analysis the GDI score was used for Pearson correlations with other variables.
Categorical variables were dummy coded in order to calculate correlations. All tests used a
significance level of p=/< 0.05. The data were analyzed using SPSS 21 (SPSS, Inc., Chicago,
IL, USA). Data analysis of the instruments were utilized as follows:
Memorial Symptom Assessment Scale. Memorial Symptom Assessment Scale
(Portenoy et al., 1994) was used to measure symptom burden (Appendix A). MSAS

subscale scores were included in the analyses. The MSAS subscale GDI, as the
measurement for symptom burden, was the continuous dependent variable and the focus of
this study.
Pearson’s Product-Moment Correlation Coefficient
The most widely used correlation index is the Pearson’s product-moment correlation
coefficient (Pearson’s r), which can be used with two variables on interval or ratio scale
measurement. The correlation coefficient clearly communicates the size of a relationship but
there are no specific rules for interpreting the strength of a correlation coefficient (Polit,
2010). An important aspect of this correlation coefficient is the ability of its square (r2) to be
a direct indication of the proportion of the variability in one variable that can be explained
by variability in another variable.
Other Measures of Association
In addition to Pearson’s r, there are other statistical measures that explain
relationships between two variables and allow inferences about relationships in the
population. For ordinal-level variables, or variables that have non-linear relationship
Spearman rank order correlation coefficient were used (Polit, 2010). Dichotomous variables
were analyzed using Point Biserial correlation or student t-tests.
Strengths and Limitations of Methods
This study is considered a feasibility study due to the limited sample size of 49,
which was short of the sample size of 85 calculated by the power analysis. Even at a
nationally recognized PAH center the sample size was not able to meet the power analysis
requirements for size. Despite this limitation this study may be the largest study looking
specifically at advanced PAH patients receiving continuous intravenous therapies.
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Protection of Human Subjects
In order to ensure the protection of each subject’s freedom from intrinsic risk or
injury and to maintain rights to privacy, and dignity a variety of human subject protective
mechanisms were utilized in this study. Coercion avoidance was achieved via verbal and
written statements that participation is completely voluntary. Approval for the proposed
study was obtained from the University of San Diego Investigational Review Board
(Appendix E), and the University of California San Diego Investigational Review Board
(Appendix F), along with an approved recruiting script (Appendix G). Patients were
assigned a personal identifier, which was used for all data entry and analysis. Only
aggregate data will be presented in publications or presentations. The findings will be used
to enhance current knowledge in the care of pulmonary arterial hypertension patients.
Summary
This quantitative research study implemented a descriptive correlational design to
identify the relationship between symptom burden, demographics, disease and treatment
related variables, and healthcare utilization. An initial estimate of 60 adult advanced
pulmonary arterial hypertension patients were anticipated to participate in this study. The
participants answered a demographic, disease, treatment, and healthcare utilization
questionnaire, as well as the Memorial Symptom Assessment Scale to measured symptom
burden. The primary investigator performed chart extraction for specific clinical and
healthcare utilization data. Data were analyzed using descriptive statistics, including
Pearson’s correlation coefficient and Spearman rank correlation coefficient.
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CHAPTER IV
Results
The purpose of this exploratory study was to (1) describe the occurrence and
characteristics (frequency, severity, and distress) of perceived symptoms using the
Memorial Symptom Assessment Scale (MSAS) among patients with advanced
pulmonary artery hypertension (PAH) and (2) to examine the relationship between
demographics (age, gender, race, education, marital status, living arrangements, and work
status), clinical characteristics [time since PAH diagnosis, medications, time receiving
intravenous prostacycline if receiving it, New York Heart Association (NYHA) functional
class, right atrial pressure (RAP), cardiac index (Cl), pulmonary vascular resistance (PVR),
and 6 minute walk test], healthcare utilization (clinic visits, emergency department visits,
and hospitalization in the previous 6-months), and symptom burden using the Memorial
Symptom Assessment Scale (MSAS) among patients with pulmonary arterial hypertension.
In this chapter a discussion of the findings will be presented in three sections. The first
section, will present a description of the sample. The second section will present a
description of PAH symptom characteristics, and finally bivariate analyses are presented.

Characteristics of the Sample
A demographic questionnaire (Appendix C) was designed to collect demographic
and personal data from participants to create a sample profile, along with a chart
extraction form for electronic medical record data collection by the PI. Patient reported
data included: age, gender, race, marital status, education, work status, living
arrangements, PAH medications, use of intravenous PAH medication, if yes, then length
of time receiving it. The chart extraction tool (Appendix D) collected the following data:
number of clinic visits in the past 6 months, emergency room visits in the past 6 months,
hospitalizations in the past 6 months, right atrial pressure (RAP), cardiac output (CO),
cardiac index (Cl), pulmonaiy vascular resistance (PVR), 6-min walk test, and New York
Heart Association’s (NYHA) functional class.
The sample included 49 PAH patients screened from PAH clinics of a large
teaching hospital during October 2013-April 2014 (seven-months). Of the patients seen
in clinic during this time 54 patients were enrolled and consented. Patients with PAH are
usually seen by their pulmonary specialist every 3 or 6 months depending on the severity
of their illness. The seven-month window of recruitment was to capture as many patients
with advanced disease and/or on multiple medical therapies, as possible. Patients not
recruited were seen in clinic when either the PI or a co-researcher was not involved in the
clinic to recruit. Of the 53 consented participants four did completed less than 25% the
questionnaires and were not included n the final analyses.

Patient Characteristics
Participant age ranged from 18 to 80 years, with a mean age of 49.5 (SD +/-14),
and a median age of 48.0, (Table 3). The sample was predominantly female (90%) and
white (61%). Other racial compositions included 27% Hispanic/ Latino, 8% African
American, 4% Asian. Marital status broken down in descending order: Married (37%),
Divorced (29%), Separated (12%), Widowed (2%), and Never-been-married (20%).
Most participants lived with family or friends (86%) versus living alone (14%). None
were in facilities. The vast majority of participants had at least some college education
(76%), 25% were college graduates, 51% had some college, 20% had some high school,
and 4% had less than a high school diploma. Two thirds of the participants work status
was classified as disabled (67%), while 14% were retired, 12% were working full-time,
and 6% were working part-time.

Table 3
Demographics o f Participants (N = 49)

Sex
Female

n
44

%
90

Male

5

10

Age, years Mean(SD)

49.5 (13.8)

Race
White
Hispanic
Other (Asian and African American)

30
13
6

61
27
12

Married
Divorced

18
14

37
29

Separated

6

12

Single—Never married

10

20

Widowed

1

2

Some high school

2

4

High school graduate

10

20

Some college
College graduate

25
12

51
25

Full-time

6

12

Part-time

3

6

Retired

7

14

Disabled

33

68

7
42

14
86

Marital status

Education

Work status

Living arrangements
Lives alone
Lives with friends/family

Clinical Characteristics
Pulmonary arterial hypertension clinical characteristics indicated the average
length of time since diagnosis for participants was 6.8 years (SD = 5.0), with a range of
less than a year to 20 years. Clinic visits averaged 2.6 (SD = 1.3) over the previous sixmonth period. A quarter of participants were admitted to the hospital with a mean length
of stay (LOS) of 9.5 days (SD = 28.1), with a range of 2 to 104 days.

Table 4
Clinical Characteristics o f Participants (N = 49), Mean, and Range
linical Characteristic
Time since diagnosis
Clinic visits
Emergency Department
visits
Hospital admissions
Length of stay (n = 12)
Right atrial pressure
Cardiac output
Cardiac index
Pulmonary vascular
resistance
6-Minute walk test
NYHA Functional
Classification System
Class II
Class III
Class IV

N (%)
49
49
49

Mean (+/■ SD)
6.8 (5.0)
2.6 (1.3)
0.5 (.8)

(Range)
(0,20)
(0,5)
(0,3)

49
12 (24.5)
48
49
49
46

0.39 (0.7)
16.4(28.1)
10.4 (4.9)
4.5 (1.4)
2.6 (0.7)
700 (348)

(0,3)
(2,104)
(2,24)
(2.1, 7.9)
(1.2,4.1)
(80,1721)

44
49

396.2 (99.4)
n

(210, 602)
%

23(46.9)
22 (44.9)
4(8.2)

23
22
4

46.9
44.9
8.2

Note. NYHA, New York Heart Association.
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Time Since PAH Diagnosis. Eighty-one percent of participants had their PAH
diagnosis for at least 10 years, while 53% of participants had their PAH diagnosed 5
years or less. Time since diagnosis in years is not a normally distributed variable
according to its skewness and kurtosis coefficients. Skewness coefficient was .902, which
is more than twice its standard error (.340). Kurtosis was -.398, which is less than twice
its standard error (.668). Thus, this variable did not meet the assumption of normality
and non-parametric test were used with this variable. Median time since PAH diagnosis
was 5 with a range of zero to twenty.
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Time Since Diagnosis (in years)
Figure 4. Time (years) since pulmonary artery hypertension diagnosis.
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Time receiving intravenous prostanoid therapy in years. Forty three percent of
participants were receiving intravenous of subcutaneous infusions of PAH medications.
Of the participants receiving continuous infusion therapy, 15 (71%) had been on
treatment for 3 years or less.
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Figure 5. Time (years) of intravenous infusion.
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Pulmonary Specialty Clinic Visits in the Previous Six-months. Forty three
percent (n= 28) of patients had 3 or more PAH clinic visits in the previous six months.

Number of Participants

zo-

Number of Clinic Visits in Previous Six-months

Figure 6. Number of clinic visits in the previous six-months.
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Emergency Department visits in the previous six months. Fifteen (31%)
participants had been to the emergency department in the previous six months for an
issue related to their PAH. The most common causes included, infected access, occluded
access, and fluid overload.
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Figure 7. Number of Emergency Department (ED) visits in previous six-months.

Hospital Admissions and Length of Stay (LOS) in the previous six-months.
Fourteen patients (29%) were admitted to the hospital for a clinical need related to their
PAH diagnosis, with a total of 12 patients staying longer than 24 hours. The median LOS
was 9.5 days with a range of 2 to 104 days. Most patients who were admitted to the

hospital (92%) were there for less than 20 days. One outlier was in the hospital for 104
days due to difficulty finding placement in the community related to the management of
their medical regimen. The total inpatient days for PAH patients were 197 days over 209
hospital days.
Right atrial pressure. The right atrial pressure, also known as central venous
pressure is a measure of the blood in the thoracic vena cava near the right atrium of the
heart. It is a surrogate for preload or the amount of blood returning to the heart and the
ability of the heart to pump the blood forward. The normal range of CVP is 0-5 mmHg.
Possible causes of an elevated CVP include an inability to fill adequately due to such
causes as congestive heart failure, hypervolemia, cardiac tamponade, or vasoconstriction,
which affects the ability of the heart to empty its chambers. Decreased pressure may be
indicative of hypervolemia (Urden et al., 2010). Right atrial pressure is a vital indictor of
right heart function and disease progression in PAH (Humbert et al., 2004). The mean
RAP for this sample was 10.43 with a standard deviation of 4.9.
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Figure 8. Right atrial pressure (RAP).

Cardiac index. Cardiac output represents the amount of blood volume pumped
out of by a ventricle. Cardiac output is a function of heart rate per minute multiplied by
the volume of blood pumped by the heart with each contraction, i.e. stoke volume
(ml/beat), e.g. CO = HR x SV. In comparison, cardiac index is the volume of blood
pumped by the heart per minute divided by the individual’s body surface area. It is
considered to be a more accurate measurement since it is based on an individual’s height

and weight. Normal Cl range is 2.2-4.0 L/min/ m2 (Urden et al., 2010), and is used as an
indicator of overall cardiac function, as well as disease progression in PAH (Humbert et
al., 2004). The mean Cl for this sample was 2.55 with a SD of .71.
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Pulmonary vascular resistance. PVR is a measure of the right heart’s afterload
or mean pressure difference across the pulmonary vascular bed, divided by blood flow.
Clinically this value represents resistance that the right ventricule must overcome in the
pulmonary arteries and arterioles in order to eject the blood and move the blood volume
forward. As the pressure in the pulmonary vasculature increase the output from the right
ventricle decreases. It is usually measured in dynes/sec/cm-5, with normal pressures
ranging from 100 - 250 dynes/sec/cm-5 (Urden et al., 2010). Increased afterload remains
a main measurement of heart failure in PAH (Subias et al., 2010, Humbert et al., 2004).
The median PVR for this sample was 640 dynes/sec/cm-5 with a range of 80 to 1721.
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Six minute walk test. The six-minute walk test is a noninvasive and simple test
measuring the distance a person is able to walk within 6 minutes. It has been found to
correlate well with functional exercise capacity, disease progression, mortality, and is an
established outcome in clinical trials (Guyatt et al., 1985; Humbert et al., 2004;
Miyamoto et al., 2000). The general cut off for poorer prognosis is a walking distance
less than 333 meters (Humbert et al., 2012). The mean distance walked in six minutes by
this sample was 396 feet with a SD of 99.5.
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PAH Medications. People living with PAH are often on combination medication
therapy, which consists of three main groups of medication: endothelin antagonists,
phosphodiesterase inhibitors, and prostanoids. In order to tease out specific symptom
characteristics related to continuous intravenous prostanoid therapy the prostenoids
medication group was divided into two. Flolan and Veletri are the medication delivered
via continuous intravenous (IV) infusion. Ventavis and Treprostinil (subcutaneous and
inhaled) are in their own category of non-intravenous (non-IV). The medication group
most often prescribed is phosphodiesterase inhibitors (59%), followed by endothelin
antagonists (55%), prostenoids IV (43%), and Prostenoids non-IV (39%). The specific
medication most often prescribed for patients in this sample is bosentan, an endothelin
antagonists.

Table 5
Pulmonary Artery Hypertension (PAH) Medications According to Medication Class
Class
Endothelin antagonists
Bosentan
Ambrisentan
Phosphodiesterase inhibitors
Tadalafil
Sildenafil
Riociguat
Prostanoids (intravenous)
Flolan
Veletri
Prostanoids (non-intravenous)
Ventavis (inhaled)
Treprostinil (subcutaneous)
Treprostinil (inhaled)

n

27
22
6
29
5
21
2
21
4
17
19
4
7
9

%
55
45
12
59
10
43
4
43
8
35
39
8
14
18
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Aim 1.
The first aim of this study was to describe the occurrence and characteristics
(frequency, severity and distress) of perceived symptoms using the Memorial Symptom
Assessment Scale (MSAS) as reported by patients with advanced pulmonary artery
hypertension. The MSAS was originally designed to measure cancer patients’ perception
of their symptoms (psychological, physical, and global appraisal) over the previous two
weeks. This was the first time, according to the literature, this measure was used with
patients with PAH. Table 12 reports the patients’ perception of their symptom experience.
Total Number of Symptoms Experienced. One hundred percent of participants
100% reported some symptomology. The average number of symptoms reported was
16.0 (SD +/- 6.8), with a range from 1 to 29 symptoms. The 10 most common in order
were: lack of energy (92%), shortness of breath (80%), feeling drowsy (78%), dry mouth
(76%), feeling irritable (74%), numbness/tingling in hands/feet (69%), difficulty
concentrating (67%), difficulty sleeping (67%), pain (63%), and cough (63%). The least
reported symptoms were mouth sores (2%), weight loss (16%), constipation (18%),
vomiting 918%), and changes in the way food tastes (20%).
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Figure 12. Total number of symptoms experienced.

The total number of symptoms experienced skewness was -.071, which is less
than twice its standard error (.343). Kurtosis was -.593, which is also less than twice its
standard error (.674). Thus this variable meets the assumption of normality.
Overall patients reported an average of 12 (SD +/- 5.3) out of 26 physical
symptoms. The number of physical symptoms reported ranged from 1 to 22 symptoms.
Most patients reported psychological symptoms (94%), with a mean number of 3.9 (SD
2.14) out of 6 possible psychological symptoms experienced. The number of psych
symptoms experienced ranged from zero to 6. Participants were given the opportunity to
report out on any symptoms not listed on the MSAS instrument. Of the 49 participants 9

(18%) reported other symptoms. These included jaw pain, flaky skin, dry eyes, sore
throat, shaking, stomach pain, joint pain, and “feeling fed up”.
The dimensions of distress, intensity and frequency provide a deeper
understanding of the symptomology of the sample. The percentage of patients who
reported higher scores (3 or 4 on a scale of 0-4) for these dimensions listed in Table 12.
The symptoms that had the highest percentages of patients describing the frequency of
their symptoms as “frequently” or “almost constantly” were, lack of energy (55%), dry
mouth (43%), difficulty sleeping (39%), numbness/tingling in hands/feet (37%), and pain
(35%).
The six highest symptoms that were reported as being experienced as either
“severe” or “very severe” were, lack of energy (82%), shortness of breath (69%), feeling
drowsy (63%), feeling irritable ((57%), difficulty sleeping (57%), and pain (57%). The
top five symptoms reported a being experienced with heavy distress (i.e. “quite a bit” or
“very much”) include, lack of energy (44%), pain (34%), shortness of breath (32%),
difficulty sleeping (31%), and diarrhea (31%).
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Table 6
Prevalence and Characteristics o f Symptoms and Total Memorial Symptom Assessment Scale (MSAS)
Scores (N = 49)

Symptoms

>t

Prevalence
(valid %)

Heavy
Frequency (%)*

Heavy
Severity (%)b

Lack of energy
Shortness of breath

45
39

92
80

51
27

82
69

Heavy
Distress
(%)'
44
32

Feeling drowsy
Dry mouth
Feeling irritable
Numbness/tingling in
hands/feet
Difficulty concentrating
Difficulty sleeping
Pain
Cough
Feeling nervous
Feeling bloated
Feeling sad
Worrying
Diarrhea
Dizziness
Lack of appetite
Nausea
Sweats
Itching
Difficulty swallowing

38
37
36
34

78
76
74
69

33
43
22
37

63
55
57
49

10
29
22
19

33
33
31
31
30
30
29
29
28
28
27
25
24
19
19

67
67
63
63
61
61
59
59
57
57
55
51
49
39
39

16
39
35
16
20
33
27
35
27
14
27
22
16
14
12

31
57
57
33
35
39
35
53
47
37
41
35
29
20
22

13
31
34
9
8
19
18
25
31
11
13
19
15
12
10

Swelling of arms or legs
Changes in skin
Problem urinating
Problems with sexual
interest or activity
Hair loss
“I don’t look like myself’

18
17
16
16

37
35
33
33

—

31
25
14
22

20
12
6
10

13
13
11

27
27
22

12
18

10
12

16

6

10
9
9
8
1

20
18
18
16
2

8
10
—
8
2

6
8
—
0
0

Changes in the way food
tastes
Vomiting
Constipation
Other symptoms
Weight loss
Mouth sores

—

8
20
—

—
—
4
—
—
—
—

Note.

Percentage of patients with symptom describing the frequency as “frequently” or “almost constantly.”
'’Percentage of patients with symptom describing the severity of the symptom as “moderately severe”
to “veiy severe.”
cPercentage of patients with symptom describing the distress associated with the symptom as “quite a
bit” or “very much.”
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Table 7
Memorial Symptom Assessment Scale (MSAS) Scores: Total Symptoms Experienced,
Total Psychological (PSYCH), and Total Physical (PHYS) Symptoms Experienced

Total Symptoms

Total PSYCH

Total PHYS

Experienced

Symptoms

Symptoms

48

48

49

1

1

0

Mean

16.0625

3.9583

12.0816

Median

16.5000

5.0000

13.0000

SD

6.81802

2.14336

5.33790

28.00

8.00

22.00

Minimum

1.00

.00

1.00

Maximum

29.00

8.00

23.00

Valid

N

Missing

Range

MSAS-PSYCH Subscale. The MSAS psychological subscale consists of the
following 6 psychological symptoms: difficulty concentrating, feeling sad, feeling
nervous, feeling irritable, worrying, and feeling nervous. First assumptions of normality
were assessed for the dependent variables of symptom burden as measured by the MSAS
subscales of MSAS-PSYCH, MSAS-PSYCH, MSAS-GDI, and Total MSAS scores.
PSYCH subscale skewness was .360, which is less than twice its standard error (.343).
Kurtosis was -.645, which is also less than twice its standard error (.674). Thus this
variable meets the assumption of normality
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Figure 13. Memorial Symptom Assessment Scale (MSAS): Psychological (Psych)
subscale average.

MSAS-PHYS Subscale. The MSAS physical subscale score is the average score
of 26 physical symptoms. Physical subscale’s skewness coefficient was .507, which is
less than twice its standard error (.350). Kurtosis was -.0.94, which is also less than twice
its standard error (.688). Thus this variable meets the assumption of normality.
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Figure 14. Memorial Symptom Assessment Scale (MSAS): Physical (PHYS) subscale
score average.

MSAS-Global Distress Index (GDI) Subscale. The MSAS’s global distress
index (GDI) subscale is purported to be a gross measure of the perceived global symptom
distress (Chang, et al., 2004; Portenoy, et al., 1994) and is comprised of the frequency
scores the following four psychological symptoms: worrying, feeling sad, feeling nervous,
and feeling irritable, as well as the distress scores from the following six physical
symptoms: pain, lack of energy, lack of appetite, constipation, feeling drowsy, and dry
mouth. The MSAS GDI subscale average score’s skewness was .186, which is less than

twice its standard error of .350. Kurtosis was -.833, which is also less than twice its
standard error of .688. Thus this variable meets the assumption of normality.

1.00

2.00

3.00

MSAS: Global Symptom Distress Subscale
Figure 15. Memorial Symptom Assessment Scale (MSAS) Global Distress Index (GDI)
subscale score average.

MSAS-Total Score scale. The MSAS total score can also be used as a measure of
symptom experience. It is the average of each symptom score across the three dimensions
of frequency, severity, and associated distress. The Total MSAS average score’s
skewness was .434, which is less than twice its standard error of .347. Kurtosis was -.067,

which is also less than twice its standard error of .681. Thus this variable meets the

Number of Participants

assumption of normality

.SO

1.00

1.50

2.00

2.SO

MSAS: Total Score Subcale (average)
Figure 16. Memorial Symptom Assessment Scale (MSAS): Total (MSAS-Total) subscale
score average.
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Table 8
Memorial Symptom Assessment Scale (MSAS) Scores: Total Number o f Symptoms
Experienced, Psychological (PSYCH), and Physical (PHYS) Subscales, Global Distress
Index (GDI), and MSAS-Total Scores.

S ta tis tic s

N

Valid
Missi
ng

Mean
Median
Std. Deviation
Minimum
Maximum

Global
MSAS:
Total
MSAS:
MSAS:
Distress
Total
Index
Symptoms PSYCH
PHYS
Score
experience Subscale Subscale Subscale Subscale
(average) (average) (average) (average)
d
48
48
46
46
47
1

1

3

3

2

16.062
16.500
6.818
1.00

1.520
1.444
.878
.27

1.389
1.266
.600
.29

1.715
1.770
.721
.48

1.327
1.247
.556
.35

29.00

3.32

3.01

3.16

2.78

Aim 2.
The second aim of this research was to examine the relationship between
demographics (age, gender, race, education, marital status, living arrangements, and
employment status), clinical characteristics (time since PAH diagnosis, medications, time
on IV prostacyclin if receiving it, New York Heart Association (NYHA) functional class,
right atrial pressure (RAP), cardiac index (Cl), pulmonary vascular resistance (PVR), and 6
minute walk test), healthcare utilization (clinic visits, emergency department visits, and

hospitalization in the previous 6 months), and symptom burden using the Memorial
Symptom Assessment Scale (MSAS) among patients with pulmonary arterial
hypertension.

MSAS- GDI Subscale
The MSAS subscale GDI was correlated with all patient demographics and
clinical characteristics as the main variable of symptom burden (Portenoy et al., 1994).
Statistically significant positive correlations were found between GDI and education (rsp
= .336(44), p = .023), work status (rsp = .349(44), p = .017), number of clinic visits (rsp
= .540(44) p = <.001). Statistically significant negative correlations were found between
GDI and six-minute walk test (r = -.383(39) p = .013), and NYHA functional class (rsp
= .421(44) p = .004). Patients with more education, who worked less or not at all, who
had more clinic visits, walked shorter distances in a six-minute walk test, and had less
functionality reported higher global distress scores.
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Table 9

Correlation of Memorial Symptom Assessment Scale (MSAS)-Global Distress Index Subscale With Demographics,

Correlation Coefficients

p value

Age

r = -.043

.777

Female

r = .078

.606

Non-white

rm-.232

.121

Higher education*

r„ = .336

.023 *

Not married

r^, = .081

.592

Lives alone

ii
o
Ul

.618
.017*

so

Not working*

a

Measure

II

Clinical Characteristics, and Healthcare Utilization Patterns

Time since diagnosis

r„ =-.196

.191

Time on intravenous

r,p= .033

.891

NYHA functional class*

rm = .421

.004**

Right atrial pressure

r = .03

.847

Cardiac index

-t
II
©
U
Ull

.720

II
I
O
K>

medications

.876

6-Minute walk test*

r = -.383

.013*

> 2 clinic visits in 6 months**

r,p*= .466

.001 **

Emergency Department visits

r = .164

.276

Hospital admissions

r = .188

.211

Diagnosis > 5 years

r„ = .186

.216

> 3 years of intravenous

r,p = .069

.648

Pulmonary vascular resistance

in 6 months, N

infusion
Note. NYHA, New York H eart Association.
r,p Spearm an’s Rho correlation,
rpb Point Biserial correlation.
r Pearson correlation.
* Statistical significant at the .05 level, ** statistical significance at the .01 level.
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MSAS-PSYCH subscale.
The MSAS PSYCH subscale was correlated with demographics and clinical
characteristics utilizing a Spearman’s rho analysis. PSYCH subscale scores were
significantly correlated with work status (rsp = .325(46) p = .024) and clinic visits (r
= .383(46), p = .007).
MSAS-PHYS Subscale.
The MSAS-PHYS subscale correlated with the following variables, NYHA
functional class (r = .551(44), p = .001), and number of hospitalizations (r = .311(44), p
= .036). It had a negative correlation with the six-minute walk distance (r = -.397(39), p
= .010).

MSAS-Total Score
The Total MSAS score correlated with work status (r = .336(45), p= .021 and the
number of clinic visits (r = .591(45), p = .001).
Total Number of Symptoms Experienced
The total number of symptoms experienced was correlated with the number of
clinic visits in the previous six-months (rsp = .392(46),/? = .006), a higher functional class
(rsp = .376 (46),/? = .008), shorter six-minute walk distance (r = .344 (41),/? = .024), and
being on endothelin antagonist medications (r^ = .365(45),/? = .012).
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More than 2 clinic visits in the last 6 months correlated with heavier overall symptom
burden. See Table 10.

Table 10
Association o f Number o f Clinic Visits, Memorial Symptom Assessment Scale (MSAS)
Scores: Psychological (PSYCH), Physical (PHYS), Global Distress Index, and Total
MSAS

Three or more
clinic visits in
previous 6 months

Pearson correlation
Sig. (2-tailed)
N
MSAS: PSYCH
Pearson correlation
Scale (average)
Sig. (2-tailed)
N
MSAS: PHYS
Pearson correlation
Scale (average)
Sig. (2-tailed)
N
Global Distress
Pearson correlation
Index (average)
Sig. (2-tailed)
N
MSAS: Total Score Pearson correlation
Scale (average)
Sig. (2-tailed)
N
Pearson correlation
MSAS: Total
Number of
Sig. (2-tailed)
Symptoms
N
Experienced

Three or more clinic visits in
previous 6 months
1

Note. *Correlation is significant at the 0.05 level (2-tailed).
♦♦Correlation is significant at the 0.01 level (2-tailed).

49
.304’
.035
48
.496"
.000
46
.466”
.001
46
.428**
.003
47
.432
.002
48

Dummy Coding. Point-Biserial correlation analysis was conducted after
collapsing and dummy coding the following variables, education into college versus no
college, race into white versus non white, marriage status into married versus not married
and work status into working versus not working. The only statistically significant
correlation found with GDI scores was work status. Work status was significantly related
to GDI scores, (rPb = .401(44) p = .006). Patients who did not work reported higher
symptom burden. For the PHYS subscale the only significant correlation was also with
work status (rPb = .432(44) p = .003). The pattern was similar for the Total MSAS scores
(r = .395(45), p = .006). Patients who did not work reported higher global symptom
burden, higher psychological and physical symptoms as well as total score for the MSAS.
New York Heart Association (NYHA) Functional Class. Due to the lower
number of participant classified as lass IV (n = 4) this variable was dummy coded into a
dichotomous variable for analysis. Point Biserial correlation was computed (Table 17).
Patients with a higher functional ability (FCII) had lower scores on the MSAS-PHYS,
and GDI subscales as well as fewer average symptoms as compared to patients in either
FC II or IV.
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Table 11
Associations Between Memorial Symptom Assessment Scale (MSAS) Scores:
Physical (PHYS), Global Distress Index, Total MSAS, Psychological (PSYCH), and
NYHA Functional Classes III & IV

NYHA Functional Class
III & IV
MSAS:
PHYS Scale
(average)

Pearson correlation
Sig. (2-tailed)
N
Pearson correlation

.509
.000
46

Global
.ill
Distress Index
(average)
.010
Sig. (2-tailed)
N
46
Pearson correlation
Total
.362
Symptoms
experienced
Sig. (2-tailed)
.012
N
48
Pearson correlation
MSAS:
.212
PSYCH Scale
(average)
Sig. (2-tailed)
.148
N
48
Note. NYHA, New York Heart Association. *Correlation is significant at the 0.05
level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed).

Independent t-tests were conducted with the recoded binary functional class.
Patients in Class II (n= 21) versus patients in class III and IV (»=25). Functional class II
participants had lower mean (SD) number of total symptoms M= 13.41 (5.93) compared
to class III and IV (M= 18.31 (SD = 6.81), t(46) = -2.63, p = .012). Patients in FC II also
had lower average MSAS-PHYS subscale scores (M = 1.06 (SD = .423) as compared to
those in FC III and IV (M= 1.67 SD= .592), t(44) = -3.919, p = .001). Patients in FC II

also had lower average MSAS_GDI subscale scores (M = 1.42, (SD = .619) as compared
to those in FC III and IV (M= 1.96 (SD= .718), t(44) = -2.703, p = .010). There was no
significant difference between the FC for average MSAS-PSYCH subscale sores. Overall,
patients with higher function (i.e. lower FC) experienced less symptom distress.
Comparison of Means. Several demographic, clinical and healthcare utilization
variables were recoded into dichotomous dummy variable for further analysis using
independent t-test or Mann-Whitney U tests as necessary. Participants who were working,
either part or full time, reported significantly lower GDI scores (M= 1.13, SD = .520)
than people not working (M= 1.85, SD = .696) (t(44) = -2.90, p = .006). Working
participants also reported lower PHYS scores (M =0.869 (SD = .347) versus non working
(M = 1.51 (SD = .582), t(44) = -3.18,/? = .003). Working participants again reported
lower PSYCH subscale scores (M = 1.287 (SD = .798) compared to non workers (M =
1.82 (SD = .9025) t(44) = -3.788, p = .035). Furthermore, patients who made three or
more pulmonary hypertension clinic visits within the previous six month had
significantly higher GDI scores (M= 2.09, SD = .615) compared to patients who had one
or two clinic visits (M= 1.42, SD =.66, t(44) = -3.49, p = .001). This pattern was similar
to PHYS subscale scores (M = 1.13 (SD = .48) versus M = 1.72 (.57) t(44) = -3.788,p
< .001), and PSYCH subscale scores (M = 1.29 (SD = .79) versus 1.82( SD = .90) t(46)
= -2.17,/? = .035). There was no significant difference between the GDI, PSYCH, or
PHYS subscale scores in the following binary categories: white versus non-white,
married versus not married, college versus no college, living alone versus with others,
less than five years since diagnosis versus five or more years, and less than 3 years
receiving continuous infusion versus thee or more.

PAH Medications Analyses. Bivariate correlations were completed with each
MSAS subscale PAH medications according to larger grouping and individual
medications. There were no significant correlations between the MSAS GDI subscale
across all medications. The MSAS PHYS subscale had a significant inverse correlation
with ambrisentan rpb = -.347(44) p = .018. The MSAS-Total subscale had a significant
direct correlation with ventavis (rpb = .310(46) p = .032 and an approach to significant
correlation with Flolan (rpb = .278(48) p = .055). The MSAS PSYCH subscale has a
correlation that approached significance with the medication ventavis (rPb = .276(46) p
= .057). Patients that were on ambrisentan had associated lower physical distress scores,
while patients on ventavis had associated higher number of symptoms, but only
approached significant correlation with higher psychological distress scores. Patients on
Flolan also had a correlation that approached significance with a higher number of total
symptoms.
Point Biserial correlation was conducted on the larger grouping of PAH
medications such as endothelin antagonists, phosphodiesterase inhibitors, intravenous (IV)
prostenoids, and non-intravenous (non-IV) prostenoids. Endothelin antagonists had a
significant negative correlation between the MSAS-PHYS (rpb = -.302(43) p = .044),
MSAS-GDI (rpb = -297(43), p = .048), and MSAS-Total subscales (rpb = -.373(45), p
= .010). Patients receiving endothelin antagonist medications for management of PAH
had an associated lower number of total symptoms, lower physical distress, and overall
distress scores.
Independent t-tests were run with the four larger groupings of PAH medications.
Patients receiving endothelin antagonists reported a statistically lower number of
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symptoms experienced (M = 13.73, SD = 6.98) as compared to patients not receiving this
type of medication (M= 18.71, SD = 5.71, t(45) = 2.634, p = .012). Patients receiving
endothelin antagonists reported significantly lower average GDI subscale scores, M =
1.52, (SD= .657) versus 1.92 (SD = .758) lower PSYCH subscale average scores M =
1.32 (SD = .86), versus 1.74, (SD = .87) or lower PHYS subscale average scores M =
1.24 (SD = .63) versus 1.55 (SD= .53) though non were statistically significant.
Medication usage was then correlated with healthcare utilization. Point Biserial
correlation revealed statistical association between patients receiving intravenous (IV)
prostanoid therapy and the number of emergency department (ED) visits in the previous 6
months (rp* = .493(47), p < .001), as well as number of hospitalization in the previous six
months (rp* = .288(47), p = .044). Mann-Whiteny U testing was then performed on these
two significant findings due to not meeting homogeneity or normality assumptions. The
distribution of the number of ED visits was not the same across the category of receiving
IV prostanoid therapy (p <.001). The distribution of the number of hospital admissions
was not the same across the category of receiving IV prostanoid therapy {p = .049).
Patients on IV prostanoid therapy had higher ED visits and hospitalizations.

Summary
This chapter presented the results of the data analysis in three sections, according
to stated aims. First, was a description of the sample demographics, clinical
characteristics and healthcare utilization patterns. Second, descriptive findings of the
MSAS and its subscales were discussed. Third, the relationships between demographics,
clinical characteristics, healthcare utilization, and symptom burden variables were

discussed. Patients living with PAH reported heavy symptom burden that was associated
with several variables, most notably not working and more than two pulmonary clinic
visits in the previous 6 months.
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CHAPTR V
Results Summary, Conclusions, Implications and Recommendations
Overview
This study employed the Revised Symptom Management Model (Dodd et al.,
2001) as its theoretical framework to study symptom burden (frequency, distress,
intensity) and overall symptom distress among participants (n = 49) diagnosed with
pulmonary arterial hypertension using the Memorial Symptom Assessment Scale (MSAS)
(Portenoy et al., 1994) as the multidimensional instrument to measure the symptom
burden experience Symptom assessment is important because symptoms directly
influence patient distress, QOL, survival, and family experience during the disease
trajectory. In this chapter the meaning and significance of the study findings, along with
comparisons in the literature will be presented. The strengths and limitations of the study
are also reviewed. Finally, the implications of the study findings and directions for fixture
research are outlined.
Symptom Burden Findings.
This is the first study utilizing the MSAS in a PAH cohort to assess symptom
burden and associated relationships with sociodemographics, clinical variables and
healthcare utilization patterns. Of the participants (n = 49), 100% reported some
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symptomology. The average number of symptoms reported was 16.0 (SD +/- 6.8), with a
range from 1 to 29 symptoms. The 10 most common in order were, lack of energy (92%),
shortness of breath (80%), feeling drowsy (78%), dry mouth (76%), feeling irritable
(74%), numbness/tingling in hands/feet (69%), difficulty concentrating (67%), difficulty
sleeping (67%), pain (63%), and cough (63%). The least reported symptoms were mouth
sores (2%), weight loss (16%), constipation (18%), vomiting (18%), and changes in the
way food tastes (20%).
The vast majority of the PAH sample reported lack of energy (92%). Of these 82%
reported experiencing it with heavy severity, yet less than half (44%) reported heavy
distress associated with experiencing lack of energy. Most of the patients in this study felt
they were experiencing severe energy loss, yet a little less than half felt this caused them
high distress levels. This may reflect the sample’s acceptance of living with a heavy
symptom burden. Previous qualitative work with PAH patients receiving continuous
intravenous epoprostenol therapy discovered themes of “figuring it out” and “giving life”
(Hall, McBean, & Purden, 2010). Almost half of this population (43%) was receiving IV
prostanoid medical therapy. Other qualitative studies with people living with PAH
revealed similar themes entitled “doing what I have to do,” “resuming life’s activities”
(Flattery et al., 2004), and “redefining life” (McDonough, Matura, & Carroll, 2011). This
may be an example of patients learning to live within the limitations of their disease, its
treatment, and appreciate what life still had to offer them.
Lack of energy is a vague symptom that can be misconstrued by those living with
or in proximity to a person with PAH. Previous qualitative studies indicated patients felt
their lack of energy was misconstrued as being lazy (Ferrari et al., 2013; Guillevin et al.,
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2013). This sometimes created distance between the patient and people around them. A
large study of people living with PAH in Europe (n= 326) revealed 26% of participants
felt misunderstood and 22% felt worthless (Guillevin et al., 2013). Caregivers and
providers need to be aware of and sensitive to the profound nature of the symptom, lack
of energy, to help mitigate further emotional and physical isolation of patients living with
PAH.
The six symptoms that were reported with heavy severity (i.e. reported as being
experienced as either “severe” or “very severe”) were, lack of energy (82%), shortness of
breath (69%), feeling drowsy (63%), feeling irritable (57%), difficulty sleeping (57%),
and pain (57%). The top five symptoms reported with heavy distress (i.e. describing the
distress as “quite a bit” or “very much”) included, lack of energy (44%), pain (34%),
shortness of breath, difficulty sleeping (31%), and diarrhea (31%). These finding may
encourage providers to dive deeper in to their patients’ symptomology. Knowing the
symptoms that are associated with higher levels of distress can help to prioritize symptom
assessment during concise clinic visits. Symptom experts such as palliative care
providers can help to mitigate symptoms, for instance pain, dyspnea, diarrhea and
problems sleeping, which had a higher occurrence of patients experiencing them at higher
levels of (i.e. heavy) severity in this study.
Recent studies measuring symptom burden with the MSAS tool in other
cardiopulmonary disease states reported a lower median number of symptoms, 9 (range
0-26) in patients with congestive heart failure (CHF) (Blinderman et al., 2008) and 10.5
(range 0-25) in patients with chronic obstructive pulmonary disease (COPD) (Blinderman
et al., 2009), as compared to patients with PAH 16.5 (range 1-29). The three most

prevalent symptoms shared among the three disease processes were, lack of energy, SOB,
and dry mouth. Overall a greater percentage of PAH patients experienced symptoms as
compared to CHF and COPD (Table 18). This underscores the heavy symptom burden of
living with PAH.

Table 12
Prevalence o f Symptoms in Pulmonary Artery Hypertension (PAH), Chronic
Heart Failure (CHF), and Chronic Obstructive Pulmonary Disease (COPD)
CHF3 (N=103)
PAH (N=49)
COPD 6(N=100)
Lack of energy 92%

Lack of energy 66%

Shortness of breath 94%

Shortness of breath 80%

Dry mouth 62%

Lack of energy 71%

Feeling drowsy 78%

Shortness of breath 56%

Dry mouth 60%

Dry mouth 76%

Feeling drowsy 52%

Cough 56%

Feeling irritable 74%

Tingling 49%

Worrying 51%

Note.a (Blinderman et al., 2008).b (Blinderman et al., 2009)

The MSAS subscales revealed moderate to severe distress in the overall sample
with wide variation in each subscale. The median (range) for the MSAS GDI 1.77 (.48,
3.16), and medians (ranges) for the MSAS-Total, MSAS PSYCH, and MSAS PHYS
were 1.24 (.35-2.78), 1.44 (.27-3.32), and 1.26 (.29-3.01) respectively. Again, these
scores indicate a distinctively higher symptom burden in comparison to other
cardiopulmonary diseases. For example the MSAS GDI median (ranges) for patients with
CHF and COPD were .9 (0,2.80) and .68 (0,1.90) respectively. The sample (n = 103) for
the CHF study included patients with a NYHA functional class (FC) of III or IV. This
PAH study consisted of almost half the patients being class II (47%) and only 8.2% in

class IV. Despite possessing better functional status, PAH patients reported distinctively
higher symptom burden across the MSAS indices (Table 19). This finding could also be
indicative of mis-categorizing of PAH patient’s functional status, which supports the
findings from Taichman et al. (2009) study, but such a large percentage (47%) of patients
being seen by a diverse group of physicians being incorrectly categorized seems unlikely.
Taken as a whole these finding underscore the particularly heavy symptom burden
experienced by patient living with advanced PAH.

Table 13
Descriptive Statistics for Memorial Symptom Assessment Scale (MSAS) Subscale Scores in
Pulmonary Artery Hypertension (PAH), Chronic Heart Failure (CHF), and Chronic Obstructive
Pulmonary Disease (COPD)

Disease Type
PAH (n = 49)
Measure

CHF° (n = 103)

COPD® (n = 100)

Possible
range of
scores
1-33

16.5 (1,29)

9 (0,26)

10.5 (0,25)

MSASGDI

0-4

1.77 (.48,3.16),

0.90 (0, 2.80)

0.68 (0, 1.90)

MSASPHYS
MSASPSYCH
MSASTotal

0-4

1.26 (.29-3.01)

0.62 (0,3.22)

0.78 (0, 2.97)

0-4

1.44 (.27-3.32),

0.63 (0,2.77)

0.56 ( 0,2.02)

0-4

1.24 (.35-2.78)

0.52 (0, 2.13)

0.75 (0, 2.80)

MSAS
symptoms
per
patient, n

Median (min, max)

Note. PHYS, physical symptom distress; PSYCH, psychological symptom distress; GDI,
global distress index.8 (Blinderman et al., 2008);b (Blinderman et al., 2009)

Correlational Findings
The global distress index subscale scores were significantly correlated with the
following variables: education, work status, number of pulmonary clinic visits in the
previous six months, six minute walk distance, and had less functionality (i.e. higher

NYHA functional class). The physical subscale scores were significantly correlated with
the following variables: time since diagnosis, number of pulmonary clinic visits in the
previous six months, hospital admissions in the previous six months, six minute walk
distance, and NYHA functional class. The psychological subscale scores were
significantly correlated with work status and number of pulmonary clinic visits in the
previous six months. The MSAS-Total subscale scores were significantly correlated with
work status and clinic visits. Finally, the total number of symptoms experienced per
patient was significantly correlated with work status, functional class, and number of
clinic visits. No significant correlation was found between pulmonary hemodynamic
parameters. This supports the findings of previous studies showing low correlation with
how patients feel and function in their lives with hemodynamics (Cenedese, et al., 2006;
Chua, et al., 2006; Taichman, et al., 2005).
Patients who did not work had significant correlation with overall heavier
symptom burden. Specifically they reported higher global distress, physical,
psychological, total scores, as well as total number of symptoms experienced.
Employment status may be an important aspect of assessing patients’ symptom burden
experience. People with lower symptom burden have better physical ability to work. The
job itself may be a distractor from the symptom experience. Further studies into the type
and amount of employment may be needed to better understand the relationship.
Several demographic, clinical, and healthcare utilization variables were recoded
into dichotomous dummy variable for further analysis. Participants working, either part
or full time, reported lower GDI (p = .006), PHYS (p = .003), and PSYCH (p = .035)
subscale scores. Furthermore, patients who made more than two pulmonary hypertension

clinic visits within the previous six months had significantly higher GDI ip = .001),
PHYS ip = <.001), and PSYCH ip = .035) subscale scores. There was no significant
difference between the GDI, PSYCH, or PHYS subscale scores in the following binary
categories: white versus non-white, married versus not married, college versus no college,
living alone versus with others, less than five years since diagnosis versus five or more
years, and less than 3 years receiving continuous infusion versus thee or more. Length of
time living with the disease or length of time receiving continuous intravenous infusion
was not associated with a heavier symptom burden. Healthcare providers need to be
aware that work status and frequency of clinic visits may be indicators for patients at
higher risk for heavy symptom burden in need of increased supportive services.
As expected patients with higher function (lower NYHA functional class)
experienced less symptom distress. Independent t-tests run with the recoded binary
functional class (FC II versus FC III and IV) revealed patients in FC II had lower mean
number of total symptoms experienced ip = .012), lower average MSAS-PHYS subscale
scores ip = .001), and lower MSAS-GDI subscale scores ip = .010). There was no
significant difference between the FC for average MSAS-PSYCH subscale sores. Overall,
patients with higher function experienced less symptom distress. These findings identify
FC III and IV patients as reporting significantly higher symptom distress and should
encourage healthcare providers to consider all FC III and IV PAH patients to be
candidates for integrating palliative care into their standard care earlier in the disease
trajectory.

PAH Medication Findings. Bivariate correlations were run with the MSAS
subscales and PAH medications according to individual medications, as well as larger
grouping of type (endothelin antagonist, phosphodiesterase inhibitors, IV prostanoid and
non IV prostanoid). There was no significant correlation with the MSAS GDI subscale
across all medications. The MSAS PHYS subscale had a significant negative correlation
with ambrisentan (rPb = -.347(44) p = .018). The MSAS-Total subscale had a significant
positive correlation with ventavis (rPb = .310(46) p = .032, and approached significance
with Flolan (rPb = .278(48) p = .055). The MSAS PSYCH subscale has a correlation that
approached significance with the medication ventavis (rPb = .276(46) p = .057). Patients
who were on ambrisentan, an endothelin antagonist, had associated lower physical
distress scores, while patients on ventavis, an inhaled prostanoid had associated higher
number of symptoms, and approached a significant correlation with higher psychological
distress scores (rPb = .276(46) p = .057). Patients on Flolan also had a correlation that
approached significance with a higher number of total symptoms (rPb = .278(48) p
= .055).
Point Biserial correlation was conducted on the larger four groups of PAH
medications such as endothelin antagonists, phosphodiesterase inhibitors, IV prostenoids,
and non-IV prostenoids. Endothelin antagonists had significant inverse correlations with
the MSAS-PHYS (rpb = -.302(43) p = .044), MSAS-GDI (rpb = -.297(43), p = .048), and
MSAS-Total subscale (rPb = -.373(45), p = .010). Unexpectedly, patient receiving
endothelin antagonist medications for management of the PAH had an associated lower
number of total symptoms, lower physical distress, and overall distress scores. One
possibility is the association between endothelin antagonists medication and lower levels

of biomarkers such as Interleukin 6 in systemic sclerosis (Bellisai, et al., 2010), which
causes symptoms such as fatigue.
Patients receiving endothelin antagonists reported a statistically significant lower
number of symptoms experienced. They also reported lower GDI, PSYCH, and PHYS
subscales average scores though none were significant. Patients receiving endothelin
antagonists such as bosentan and ambrisentan experienced lower symptom burden
compared to patients not receiving this group of medications.
Patients receiving ambrisentan medication had lower physical distress scores,
while patients on ventavis reported a higher number of symptoms, and approached a
statistically significant correlation with higher psychological distress scores. Patients on
Flolan had a correlation that approached significance with a higher number of total
symptoms. Healthcare providers need to be aware of possible heavier symptom burden
for patient using ventavis. This inhaled medication may need to be delivered up to 9
times a day with each dosing requiring five to ten minutes to deliver. Increased education
and support may be required for these patients. Further studies into possible non
adherence being a causative factor needs to be done.
Analyses of relationships between PAH medication use and healthcare utilization
revealed significant findings. Patients on IV prostanoid therapy had higher ED visits and
hospitalizations, mostly related to central-line occlusion, infection or fluid overload.
These finding support the need for increased support for patients receiving continuous IV
therapy. The distribution of the number of ED visits was not the same across the category
of receiving IV prostanoid therapy (p <.001). The distribution of the number of hospital
admissions was not the same across the category of receiving IV prostanoid therapy (p
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= .049). Patients on IV prostanoid therapy had a higher number of ED visits and
hospitalizations.

Research Strengths and Limitations
This study is the first study to use the MSAS for symptom assessment in patients
diagnosed with PAH. Presently the Cambridge Pulmonary Hypertension Outcome
Review (CAMPHOR) (Gomberg-Maitland et al., 2008) is the measure used in clinical
trials for measurement of health related quality of life (HRQOL) in persons living with all
types of pulmonary hypertension, not just PAH. This instrument was shown to have
reliable and valid scores yet it does not allow for answers to be on a continuum and may
miss out on more detailed information. Respondents mostly may choose only
dichotomous answer choices; true/false or yes/no answers. Previous studies in PAH have
pointed out the shortcomings of the (CAMPHOR) to adequately assess symptomology
(Matura et al., 2014). The MSAS provides a more in-depth understanding of the symptom
experience and its dimensions of severity. There is also no measure of the associated
distress from the symptoms, which is a vital aspect of the Revised Symptom Management
Model (Dodd et al., 2001).
Limitations. This study has several limitations. First the sample size was less
than the 85 calculated with the power analysis and was a convenience sample from a
single site. Institution-based differences in treatment or patient population may limit this
study’s generalizability. The predominance of females (90%) may have also diminished
the generalizability. Similar studies with larger PAH patient samples (n =326 and n = 191)
had 75% and 85% female participants respectively (Guillevin et al., 2013; Matura et al.,
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2014a), as well as the REVEAL registry which also shows similarities in the therapeutic
management of this cohort with a national PAH registry (Barst, et al., 2013).
The MSAS scores have not been validated for patients with PAH. One of the
symptoms in the GDI subscale is constipation. In patients with PAH, diarrhea is a
common (57%) symptom with 47% reporting high severity in this sample. Constipation
was reported by only 18% of the sample and only 10% reported the constipation being
very severe. This underscores the importance of using a psychometrically tested, disease
specific tool for measuring symptom burden in patients living with PAH.
Healthcare utilization patterns looked at only the incidences directly related to
patients’ PAH diagnosis or treatment. Measuring all clinic visits, emergency room visits
and hospitalization may have provided a deeper picture of this sample’s healthcare needs
and utilization. This study did not measure comorbidities, which may have elucidated
relationships between certain comorbidities and heavier symptom burden. A more
indepth look at healthcare utilization with comorbidities in PAH would be important
information to have in identifying patients in need of increased support.
Conclusions
Patients living with PAH experience distinctively heavier symptom burden in the
occurrence, frequency, intensity, and distress associated with their symptoms overall as
compared to those with other cardiopulmonary disease, such as CHF and COPD. A
general sense of profound lethargy was prevalent in this sample as measured by the high
occurrence and severity reported with symptoms such as lack of energy, shortness of
breath, difficulty sleeping, and feeling drowsy. Caregivers and providers need to be
aware of the intense nature of fatigue in patients living with PAH. Patients may learn to
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live within the limitations of the disease and its treatment, thus making overt displays of
symptomatology subtler and more difficult to assess and appreciate. Better education to
caregivers and families make help to prevent misunderstanding and improve family
cohesiveness.
Close to half of participants (43%) had three or more clinic visits in the previous
six months. This finding was highly related with all measure of symptom burden. Higher
clinic visits along with non-working status and NYHA FC III and IV were all better
clinical indicators of heavy symptom burden than hemodynamic such as right atrial
pressure, cardiac index, and pulmonary vascular resistance. This supports the Revised
Symptom Management Model (Dodd, et al., 2001) purported relationship between
functional status, which is considered a symptom outcome, increased clinic visits which
could be considered a symptom management strategy, and work status, which is a
representation of the person and their environment.
Pulmonary arterial hypertension may be considered an orphan disease but it
posses heavy symptom burden for the patient and heavy healthcare utilization for the
healthcare system. Forty three percent of this sample (N = 21) were receiving continuous
IV therapy. These patients had significantly higher emergency department visits and
hospitalizations. The sickest 10% of the US population accounts for more than half of its
healthcare expenditures (Zuvekas & Cohen, 2007). Earlier identification of patients living
with PAH experiencing heavy symptom burden can benefit the patient and their family
foremost, but may also help to achieve the Institute of Healthcare Improvement’s (IHI)
triple aim of: improving patients’ experiences of care (including quality and satisfaction),
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improving the health of populations, and reducing the per capita cost of healthcare
(Berwick, Nolan, & Whittington, 2008).
Patients receiving endothelin antagonist medications experience a lower number
of total symptoms and less psychological distress. Patients receiving an inhaled
prostanoid (ventavis) reported a higher number of symptoms. Patients on IV prostanoid
(Flolan) had a correlation that approached significance with a higher number of total
symptoms. Patients receiving prostenoids whether inhaled or IV require a deeper
assessment of their symptom burden to identify the need for increased supportive services.
These findings underscore the heavy symptom burden experienced by patients
living with PAH. Once patients are classified as NYHA FC III or higher they could
benefit from integration of palliative care into their standard care. According to the
Center to Advance Palliative Care (CAPC) (2014) palliative care is a medical
subspecialty providing patient relief from the symptoms, pain, and stress of serious
illness with the goal of improving quality of life for both the patient and the caregiver.
Integration of palliative care has been shown to increase quality of life, decrease
depression and aggressive care at end-of-life, as well as increase life expectancy in other
diseases (Temel, et al., 2010). It is time to study the impact palliative care can have in the
lives of people living with PAH.

Implications for Nursing Practice
Nurses caring for patients with PAH need to advocate for improved palliative care
integration earlier in the disease trajectory. People in functional class III or higher are at
greater need of the supportive services palliative care provides. Palliative care provides

101

patient and family centered care by having discussions about goals of care and then
working to ensure the care provided is aligned with the established goals. Bedside nurses
can advocate for palliative care consults for PAH patients in NHYA FC III or IV by
talking with the pulmonary team and educating them about the ways palliative care can
improve the patient and caregivers quality of life.

Future Research and Policy
A reliable and validated instrument to measure symptom burden in PAH is still
needed. This feasibility study has underscored the association of heavy symptom burden
of people diagnosed with PAH with higher levels of medical support and /or in higher
functional classes II or IV. Larger studies to elucidate strong predictors of heavy
symptom burden are needed to better identify patients in need of palliative care earlier in
the disease trajectory of PAH are needed.
The large International PAH Patient and Carer Survey (n = 362) made
recommendations for a more multidisciplinary health care team to provide the
comprehensive care PAH patients require for optimal management and treatment of their
disease (Guillevin et al., 2013). A large, multi-center, randomized controlled trial
measuring disease progression, QOL (of patients and caregivers), and healthcare
utilization metrics comparing integration of an interdisciplinary palliative care team into
standard care for functional class III or higher patients, versus standard PAH care may
provide the empirical evidence needed to change care for the better, on a larger scale.

This is the first study to describe associations between symptom burden and
healthcare utilization more research is needed to further understand and mitigate the
heavy symptom burden of PAH.
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APPENDIX B
Demographic Data Sheet
Directions: These questions concern the backgrounds o f those who respond to this questionnaire.
As with all answers to this survey, your responses will be kept confidential. Please circle the
appropriate letter or fill in the blank.

1.What is your gender? (circle one):
Female
Male
2. What is your age? ____________________
3. What is your race or ethnicity? (Circle all that apply)
White
African-American/Black
Hispanic/Latino

Asian

Other

4. What is your current marital status? (circle one):
Married
Divorced
Separated
Widowed
Single-never
married
5. Living arrangements (circle one):
Lives alone
Lives with family/friends
Lives in facility
6. How many years of school have you received? (circle one):
College graduate
Some college
High school graduate
Some high
school
7. What is your work status? (circle one):
Fulltime
Part-time
Retired
Student
Disabled
8. What is your Insurance Coverage (circle one)
Medicare
Medical
Commercial/private
Other
9. How long ago were you diagnosed? (month /year of diagnosis or time since
diagnosis)______________________________________________________________________
10. If you are on continuous infusion (SQ or IV) how long have you been on it? (months or
date)____________________________________________________________________________
11. How many doctor’s appointments in the past 6 months? (circle one):
0
1
2
3
4
5
<5
lO.How many trips to the emergency room in the past 6 months? (circle one):
0
1
2
3
>3
1l.W hat was the reason for the visits?

12.How many hospital admissions in the past 6 months? (circle one):

0

1

2

3

>3

13.What was the reason for the admission?
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APPENDIX C
Memorial Symptom Assessment Scale
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AND MOICATE HOW MUCHTHE SYMPTOM HAS DISTRESSED OR BOTHERED YOU.
Other
Other
OSwr

s
•

i
<
1
1
1
1

«
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APPENDIX D
Chart Audit Tool

Chart Audit Measure (To be done by the PI)
1.

RAP_________________________________ Date of heart
catheterization_______________________

2.

CO_______________________________________________

3.

C l________________________________________________

4.

PVR______________________________________________

5.

Six minute walk test________________________________ Date_

6.

Comorbidities___________________________________________

7.

Functional Status_________________________________________

8.

PAH Type______________________________________________

9.

PAH medications________________________________________

Health care Utilization Pattern Chart review
1.

Number of hospitalization in the past 6 months_________________

2.

Reason for admission_____________________________________
a.

Hospital LOS____________________________________

3.

Number of ED visits in the past 6 months______________________

4.

Reason for ED

5.

Number of clinic visits in past 6 months_______________________
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APPENDIX F
University of San Diego Institutional Review Board Approval Letter
130873

UNIVERSITY OF CALIFORNIA, SAN DIEGO
HUMAN RESEARCH PROTECTIONS PROGRAM

TO:

Dr. Michael Madam

RE:

Project #130873

Predictors o f Synytam Borden in Pulmonary Artehal Hypertension
Dear Dr. Madam:
Th»

r* * y <’* "* * —

d— *

hy tm m n f Ifci. imtjriairiV

» « iw »

Tlnanli in i <imiIsih I irilti Ihr mq"*™— ■
«%■
"'f
Homan Subjects (45 CFR 46 and 21 CFR 30 and 36), mrlndmg it* relevant Safaparts. This approval,
bated on the degree o f tide, it for 365 days from the date of IRB review and approval unless otherwise
■toted in this ktter. The regulations require that continuing review be conducted an or before the 1-year
anniversary dale o f the IRB approval, even toon^t die research activity may not begin until aome time
after tbe IRB has given approval.
The Committee notes that this study is closed to accrual; re-approved consent forms will not be provided
to toe PL
The IRB determined toat this project presents no more toan minimal risk to fanman subjects in toat foe
probability and magnitude of harm or discomfort amicipaled in toe research are not peater in and of
foemaelve* than foosc ordinarily encountered m daily hfe or dutmg the performance o f routine physical or
psychological examinations or tests.
Date of IRB review and approval: 7/17/2814
On behalf of toe UCSD Institutional Review Boards,

Kevin “Casey71Cox
Acting Director
UCSD Hamsn Research Protections Program
(838) 637-3100; hrpp3ucsd.edu
Note: IRB qiproval does not constitute fonding or otoer institatianal required approvals. Should jonr
studies involve other review committees such as Office o f Clinical Trials Administration (OCTA), Office
of Coverage Analysis Administration (OCAA), Conflict o f Interest (CQI), Protocol Review Monitoring
Committee (PRMC), and committees ander Environmental Health A Safety (EHAS) sndi as Instjtntional
Biosafety Committee (IBC), Hnman Exposure Committee (HERC), aad RSSC (Radiatinn Safety and

125

Swvdllaoce Committee), it is die researchm rrsponabiUty to ensine that sll yprovils ire in place pnor
to conducting research involving hnmac subjects or (heir related sporimms.
Approval release date: 7/24/2014

APPENDIX G
University of San Diego Institutional Review Board Approved Recruiting Script

Project # 130873 Predictor of Symptom Borden in Pulmonary A rterial Hypertensi

Requested Brief Recruiting Script

Hello My name is...(Catherine Madam or Sandra Lombardi) a m ine here at UCSD.
I am here today to tell you about a study that I am conducting with Michael Madam. We want to
understand what it is like to live with pulmonary arterial hypertension, in particular, what it is
Idee to live with die symptoms associated with die disease. With a better understanding o f what it
is like to live with the disease and specific medical markers (for example pulmonary pressures
and right heart function), we are hoping to be able to identify people who might benefit from
additional supportive care in combination with their present medical care earlier in the disease
process, such as palliative care. This study's goal is to better understand what it is like to live
with pulmonary artenal hypertension and hefri identify people who may need extra supportive
services.
If you are interested in participating I have some paper work that I would need you to fill out
starting with the consent, which I will be happy to go through with you ....

